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ABSTRACT OF THE DISSERTATION 
 
The Role of Hspa9 in Mouse Hematopoiesis and IL-7 Receptor Signaling 
by 
Kilannin Cathleen Krysiak 
Doctor of Philosophy in Biology and Biomedical Sciences, Molecular Genetics and Genomics 
Washington University in St. Louis, 2014 
Associate Professor Matthew J. Walter, Chair 
 
HSPA9 was previously identified as a candidate gene in a commonly deleted region (CDR) 
associated with myelodysplastic syndrome (MDS), a clonal hematopoietic stem cell disorder. 
Cytogenetic abnormalities occur in ~50% of MDS patients and an interstitial deletion or loss of 
chromosome 5 containing HSPA9 is the most common, occurring in up to 25% of patients. In 
order to understand the role of HSPA9 in hematopoiesis and disease development, we created 
an Hspa9 knockout mouse model. We characterized hematopoiesis of heterozygous mice 
(Hspa9+/-), which have a 50% reduction in Hspa9 expression, modeling the heterozygous loss of 
HSPA9 and 50% reduction in mRNA observed in MDS patients. Homozygous knockout of 
Hspa9 is embryonic lethal prior to fetal liver hematopoiesis, preventing further evaluation of 
hematopoiesis in Hspa9-/- mice. 
 
Analysis of stem, progenitor and mature stages of hematopoiesis up to 18 months of age 
identified no significant differences in Hspa9+/- mice compared to Hspa9+/+ littermates in vivo. 
However, as early as 2 months of age, Hspa9+/- mice have a significant reduction in CFU-PreB 
colony formation in vitro, indicating a B-cell progenitor defect. This reduction in colony formation 
is hematopoietic-cell intrinsic and likely due to a functional B-cell progenitor defect, since B-cell 
progenitor frequencies in Hspa9+/- mice are normal. Gene expression array analysis revealed a 
reduction in gene expression pathways associated with proliferation and activation of B-
 xii	  
lymphocytes. Gene expression analysis of hematopoietic progenitor cells from MDS patients 
also identified B-cell signaling pathways as the most down-regulated pathways. IL-7 added 
exogenously to CFU-PreB cultures was able to partially rescue the reduction in Hspa9+/- CFU-
PreB colony formation, further indicating dysfunctional IL-7 signaling in Hspa9+/- B-cells.  
 
To explore the contribution of Hspa9 to altered IL-7R signaling, we interrogated an IL-7 
dependent cell line treated with an Hspa9 or non-targeting control siRNA. Knockdown of Hspa9 
resulted in a significant growth defect in these cells and reduced Stat5 phosphorylation following 
IL-7 stimulation of cytokine-starved cells. Collectively, these data implicate Hspa9 in IL-7R 
signaling in B-cells. Further work will determine whether HSPA9 loss contributes to the 
reduction in B-cell progenitors and increased B-cell apoptosis observed in patients with MDS.  
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1. Myelodysplastic Syndromes 
1.1. Disease statistics 
Patients with myelodysplastic syndromes (MDS) have a clonal hematopoietic stem cell 
(HSC) disorder that results in dysplastic hematopoietic cells in their bone marrow as well as 
peripheral blood cytopenias1,2. Commonly occurring in older individuals (20-36/100,000 in 
>70 year olds), MDS is associated with an increased risk of transformation to acute myeloid 
leukemia (AML)3-5. Ultimately, 30% of MDS patients will progress to a highly-chemotherapy 
resistant form of AML5. The World Health Organization (WHO) and French-British American 
(FAB) classification systems are used for the diagnosis of MDS subtypes based on clinical, 
cytochemical, immunophenotypic, morphologic and genetic information6-8. These, in 
conjunction with the International Prognostic Scoring System (IPSS) or the recently released 
revised IPSS (IPSS-R), are used to predict an individual patient’s prognosis9,10. Despite the 
utility of such systems, we need a better understanding of MDS pathogenesis to improve 
treatment options and better predict patient outcomes.  
 
1.2. Genetics 
The genetic events leading to the development of MDS and the subsequent transformation 
to AML are poorly understood. However, approximately 50% of MDS patients have an 
acquired cytogenetic abnormality, highlighting the role of genetic alterations in disease 
pathogenesis2. These cytogenetic abnormalities are a key prognostic factor in both MDS 
and AML transformation, and while prognostically important, they alone do not provide 
mechanisms of pathogenesis2. With more recent applications of next-generation sequencing 
technology, additional mutations have been identified in patients both with and without a 
cytogenetic abnormality, greatly expanding our understanding of the genetics of MDS11-14. 
One of these studies highlighted the complexity of MDS and its evolution by dissecting its 
clonal architecture in serial samples13. Deep sequencing of 15 secondary AML genomes, 8 
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of which were also analyzed at the MDS stage, were used to identify founder clones and 
subclones. Founder clones produce subclones as malignant cells undergo self-renewal and 
produce progeny. While some genes tend to occur in the founding clone, no commonly 
mutated genes were identified to always be associated with either the founding clone or 
subclones. Such heterogeneity in clonal architecture and evolution means mutations in MDS 
cannot be simply thought of in binary terms of absent or present. This greatly complicates 
how we interpret and treat the mutational spectrum of MDS patients. Deep sequencing 
studies also reveal a much higher percentage of bone marrow cells involved in the disease 
clone than described by the blast percentage that is currently used for diagnosis and 
prognosis. Taken together, these discoveries have greatly expanded our understanding of 
the complexity of MDS; however, the functional and clinical implications of these discoveries 
are still being investigated. 
 
1.2.1. Gene level mutations 
Recent advances in sequencing technology have reduced costs and increased 
sensitivity, allowing for genomic studies of large cohorts of MDS patients at the 
nucleotide level. These studies have revealed not only the clonal heterogeneity of MDS 
but also identified novel mutations associated with MDS11-14. The largest category of 
recently identified mutations involves splicing machinery, effecting up to 50% of MDS 
patients15-18. Sequencing of candidate genes in large cohorts has been able to identify 
mutations or cytogenetic abnormalities in up to 90% of patients14. As we understand 
more about the genetics of MDS, we must understand how these mutations individually 
and in combination effect hematopoiesis and drive disease. 
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1.2.2. Chromosomal abnormalities 
While recent technological advances have identified individual genes commonly mutated 
in MDS, the clinical application of this information is still being determined. However, 
cytogenetic analysis has been standard practice for diagnosis and prognosis of MDS for 
decades. Cytogenetic abnormalities are identified in approximately 50% of MDS 
patients2. As part of the original IPSS, patients were given a score based on three 
cytogenetic categories that would factor into their overall prognosis and included several 
of the most common cytogenetic abnormalities9. The IPSS-R now stratifies patients into 
five cytogenetic categories and incorporates more rare cytogenetic abnormalities10. 
Regardless, having 3 or more cytogenetic abnormalities has been consistently 
associated with poor prognosis. Common cytogenetic abnormalities in MDS include 
del(5q), -7/del(7q), trisomy 8 and del(20q), all of which occur in both isolation and in 
complex karyotypes2. Del(5q), the most common of these cytogenetic abnormalities, is 
our focus. 
 
1.2.2.1. Del5q 
Approximately 15-25% of MDS patients have an interstitial deletion or loss of the 
long arm of chromosome 5 (5q)2,13,19,20. This frequency places it among the most 
frequently acquired mutations identified in MDS, indicating the importance of 
understanding its contribution to this disease11,13. There are two commonly deleted 
regions (CDR) on 5q20-28. The distal CDR on 5q33.1 is associated with 5q minus 
syndrome, which has a good prognosis and a low risk of AML transformation20,22,29. 
Alternatively, the proximal CDR on 5q31.2 is associated with a high risk of AML 
transformation20,24-27 (FIGURE 1.1).  
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1.2.2.1.1. Haploinsufficiency 
The interstitial deletions on chromosome 5 are single copy losses, and no 
biallelic disruptions of genes in either the proximal or distal regions have been 
identified, implicating haploinsufficiency as the underlying genetic 
mechanism20,26,27,30,31 (TABLE 1.1). In both regions, genes that contribute to 
features of MDS have been successfully identified21,32-36. However, none of them 
can fully explain the clinical phenotypes observed, suggesting that multiple genes 
on the interval contribute to pathogenesis33.  
 
1.2.2.1.2. Association with TP53 
Recent next-generation sequencing has also identified the frequent co-
occurrence of TP53 mutations with del(5q)12,13,37-39. Earlier studies had identified 
TP53 mutations associated with del(5q) in patients with poor prognosis, 
specifically with either therapy-related MDS and AML or refractory MDS and 
AML38,40-42. Loss of 5q clearly preceded mutations identified in TP53 in one 
patient. This patient, as well as data supporting loss of 5q as an early event in 
MDS development, indicates TP53 mutations may be a transforming event 
following establishment of a del(5q) MDS clone41,43,44.  
 
1.2.2.2. Genes implicated in the pathogenesis of del(5q) MDS 
Genes on del(5q) that have been implicated in that pathogenesis of MDS, including 
the two CDRs, are illustrated in FIGURE 1.1, and the studies supporting their 
involvement are listed in TABLE 1.1. 5q deletions are often large, resulting in the 
CDRs being defined by a small number of patients, implicating additional genes that 
reside on 5q outside the two commonly described CDRs (including NPM1 and 
APC)34,45-48. As described above, the distal CDR is associated with 5q- syndrome, a 
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phenotypically defined subtype of MDS consisting of refractory macrocytic anemia, a 
normal or high platelet count, hypolobated megakaryocytes, and del(5q) as the only 
cytogenetic abnormality6. Reduced expression of Rps14, miR-145/146A and Sparc 
recapitulate phenotypes associated with 5q- syndrome as detailed in TABLE 
1.132,35,49,50. Studies of genes in the proximal CDR, 5q31.2, associated with high-risk 
MDS have identified EGR1 and CTNNA1 as genes in this region that may contribute 
to hematopoietic dysfunction, also detailed in TABLE 1.121,30. Consistent with 
haploinsufficiency, Graubert et. al. identified 7 genes, including CTNNA1 and HSPA9, 
whose mRNA were significantly reduced in CD34+ cells from MDS patients with 
del(5q) relative to normal CD34+ cells by microarray analysis, which are shown in 
red in FIGURE 1.126. Collectively, several genes on chromosome 5q impact 
hematopoiesis and suggest that more than one gene may contribute to the 
phenotypes associated with MDS.  
 
1.2.2.2.1. Identification of a candidate gene on the proximal CDR 
In order to investigate the impact of reduced expression of genes on the interval 
in hematopoiesis, we performed an shRNA screen of genes in this interval. 
Utilizing 3-5 independent shRNA constructs available for 22 of 28 protein coding 
genes on the interval, we reduced expression of each gene in primary human 
CD34+ cells in erythroid differentiation media and evaluated differentiation by 
flow cytometry (CD71/GpA). HSPA9 was identified as the top-scoring gene of the 
22 assayed that met the following criteria: targeted shRNAs in our erythroid 
differentiation assay resulted in a ≥1.5 fold reduction in mature erythroid cells 
relative to control shRNA (CD71+/GpA+)(8/22), the gene was normally 
expressed in CD34+ cells at the mRNA level (15/21), and it had ~50% 
expression in CD34+ cells from del(5q) MDS patients compared to normal control 
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marrow (7/22). For these reasons we chose to further investigate the role of 
HSPA9 in hematopoiesis. 
 
2. HSPA9 
2.1. HSP70 family of proteins 
HSPA9 is a member of the HSP70 (heat shock protein 70 kD) family of chaperone proteins. 
This highly conserved family of proteins plays an essential role in protein homeostasis and 
cellular stress response51. Members of this family are involved in protein transport, organelle 
import, folding, disaggregation and sequestration52-55. Although not all eukaryotic HSP70 
proteins are heat-inducible, they respond to a variety of cellular stresses52,53,55,56. The protein 
products of this multi-gene family are located in multiple compartments of the cell where 
they perform different functions. It is clear by their sequence differences that many of these 
family members were the result of gene duplication events that have been maintained 
throughout evolution54,57,58.  
 
2.1.1. Structure and mechanism 
The highly conserved domains of HSP70 proteins serve different functions. The 
nucleotide binding domain (NBD) is the site of nucleotide exchange as well as the 
location of most co-chaperone interactions (FIGURE 1.2). The flexible linker region 
facilitates allosteric regulation and communication of the domains. The substrate binding 
domain (SBD) is the site of client protein binding and interacts with exposed hydrophobic 
residues on client proteins. Finally, the C-terminal lid domain is involved in client protein 
affinity. The functions of these domains work together to perform the substrate binding 
and nucleotide exchange necessary for HSP70 family functions53,59,60.  
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Members of the HSP70 family of proteins are key regulators of protein homeostasis. 
They are involved in protein unfolding, disaggregation, stabilization, folding, membrane 
translocation, transport and targeting for degradation59,61. They bind and release proteins 
through an ATP-dependent functional cycle common to this family and depicted in 
FIGURE 1.3. ATP hydrolysis of HSP70 proteins is extremely slow without the help of co-
chaperones. J-domain proteins (also known as HSP40 proteins) bind to the nucleotide 
binding domain (NBD) of HSP70 proteins and assist in initial binding of client proteins62. 
When the HSP70 protein binds a client protein in the SBD, a global conformational 
change occurs, enhancing ATP hydrolysis at the NBD63. ATP hydrolysis of the NBD 
enhances affinity for the substrate by closing the lid domain. Finally, another co-
chaperone acts as a nucleotide exchange factor (NEF) and catalyzes the release of the 
substrate by ADP-ATP exchange.  
 
While this functional cycle is common among all HSP70 family members, differences in 
cellular localization as well as client and co-chaperone specificity provide unique roles 
for the human HSP70 family members. 
 
2.1.2. Human HSP70 genes 
The human genome produces 8 proteins that fulfill the basic structural criteria for a 
conserved HSP70 family protein as described in Section 2.1.1. However, transcripts are 
generated from an additional 9 genes with either incomplete or highly divergent 
substrate binding domains, which will not be discussed here64,65. The human genome 
produces 6 cytosolic (HSPA1A, HSPA1B, HSPA1L, HSPA2, HSPA6, HSPA8), 1 
endoplasmic reticulum (HSPA5) and 1 mitochondrial (HSPA9) enriched HSP70 
proteins53,64.  
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While HSP70 family members are highly conserved, their functions are clearly not 
redundant. Murine knockout of Hspa8 and Hspa5 are known to be embryonic lethal, and 
loss of the testis-specific Hspa2 results in male infertility60,66-68. However, Hspa1a, 
Hspa1b and Hspa2 knockout mice are all viable. Hspa6 and Hspa1l knockout mice have 
not yet been described69-71. Lastly, Hspa9 knockout mice have not been described prior 
to this work. 
 
2.2. Cellular localization and expression 
The ubiquitously expressed HSPA9 is present in a variety of subcellular locations including 
the mitochondrial matrix, endoplasmic reticulum, cytoplasmic vesicles and cytosol72-74. 
Although HSPA9 has been shown to have cytoplasmic functions, its primary localization is in 
the mitochondria where it functions in mitochondrial protein import75-78. Unlike other HSP70 
proteins, HSPA9 has an N-terminal 46-amino acid mitochondrial targeting sequence (MTS) 
that is required for mitochondrial import (FIGURE 1.2)73,76. HSPA9 is the only mitochondrial 
HSP70 protein described in most eukaryotes, yeast being a notable exception, attributing to 
its highly conserved functions observed across species.  
 
2.3. Homology/conservation 
HSPA9 is highly conserved as illustrated by TABLE 1.2. Studies utilizing S. cerevisiae have 
provided many useful insights into the function of HSPA9. However, unlike most other 
eukaryotes that have one mitochondrial HSP70 protein, yeast have three HSP70 family 
proteins that localize to mitochondria (Ssc1p, Ecm10p, Ssq1p)79. Ssc1p shares the greatest 
homology with human HSPA9, sharing 65.8% identity at the protein level. Ssc1p is involved 
in mitochondrial import, protein folding and protein degradation, functions that are described 
in Sections 2.5.1 and 2.5.2. SSC1, the gene encoding Ssc1p, is an essential gene in yeast. 
ECM10 is a paralog of SSC1 resulting from a whole genome duplication event. Ecm10p has 
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been implicated in mitochondrial import, shares 82% identity with Ssc1p and 63.4% identity 
with HSPA9 at the protein level, and when overexpressed can rescue SSC1 mutants. 
However, ECM10 is not an essential gene and has only been described to have overlapping 
function with SSC1. For these reasons ECM10 will not be discussed further79,80. The third 
protein, Ssq1p, only shares 48.8% identity with HSPA9 and has no closer mammalian 
homolog. Ssq1p is 1000-fold less abundant than Ssc1p but has a highly specified role in 
iron sulfur (Fe-S) cluster biosynthesis81. Overexpression Ssc1p can rescue Fe-S cluster 
biosynthesis, indicating Ssc1p (and possibly HSPA9) may be involved in this process79. 
Functional evidence for HSPA9’s role in Fe-S cluster biosynthesis is presented in Section 
2.6.2. 
 
2.4. Co-chaperone specificity 
Even though HSPA9 is highly conserved, its function and specificity can be altered by its 
interactions with co-chaperones, indicating HSPA9 may not have entirely overlapping 
functions across all species. Just as different HSP70 family members have different co-
chaperone specificity, HSPA9 utilizes different co-chaperones to mediate different functions 
within the same cell. As described in the following sections, HSPA9’s role in mitochondrial 
import and mitochondrial protein folding are among its most well characterized functions. 
For these roles, HSPA9 utilizes the nucleotide exchange factor GRPEL1; however, different 
J proteins are utilized to aid in substrate binding and ATP hydrolysis. For mitochondrial 
import, J proteins DNAJC19 and DNLZ (better known as PAM18 and HEP1, respectively) 
are used, while for mitochondrial protein folding HSPA9 utilizes DNAJA363,82-84.  
 
2.5. Mitochondrial protein import and homeostasis 
2.5.1. Translocase of the inner membrane (TIM)/Translocase of the outer 
membrane (TOM) 
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HSPA9’s role in mitochondrial import is highly conserved and well described. The 
majority of mitochondrial proteins are encoded in the nucleus and must be imported to 
the mitochondria. For mitochondrial import into the mitochondrial matrix to occur, 
proteins must pass through two highly regulated membranes. Multi-protein complexes 
known as the translocase of the outer membrane (TOM) and translocase of the inner 
membrane (TIM) regulate the translocation of proteins across these membranes85,86. 
Proteins targeted to the mitochondria first pass through the TOM complex to reach the 
intermembrane space. Precursor proteins with N-terminal presequences are sorted and 
directed by additional protein complexes to the appropriate TIM complex, which will 
insert them into the inner mitochondrial membrane or translocate them into the 
mitochondrial matrix. 
 
HSPA9 works in concert with the TIM23 translocon to facilitate translocation of proteins 
from the intermembrane space to the mitochondrial matrix87,88. The process is depicted 
in FIGURE 1.4. A pH gradient between the matrix and intermembrane space starts this 
process by translocating the positively charged N-terminal presequence of the precursor 
protein89,90. ATP-dependent binding of HSPA9 to the precursor protein is required to 
complete translocation78,91-93. The membrane-spanning heterodimer PAM16/18 and 
matrix protein TIM44 tether HSPA9 to the TIM23 translocon, where it binds the incoming 
presequence of the matrix protein87,94. For its mitochondrial import function, PAM18 is 
recognized as HSPA9’s J protein and GRPEL1 acts as its nucleotide exchange factor. 
Together, these proteins are known as the presequence translocase-associated motor 
(PAM), of which HSPA9 is the core component. The PAM complex is required to 
complete the ATP-dependent translocation of these precursor proteins; however, the 
exact mechanism of how HSPA9 facilitates transfer of the incoming protein is a subject 
of much debate. 
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Two models were initially proposed for how HSPA9 interacts with incoming proteins. The 
first suggests that proteins can move in either direction through the TIM23 complex, but 
HSPA9 clamps down on the incoming preprotein, preventing it from sliding back into the 
intermembrane space. As additional HSPA9 molecules are recruited to the protein, it 
becomes trapped in the matrix95,96. The other describes HSPA9 as pulling the preprotein 
into the matrix by acting as an active import motor97,98. Regardless of its mechanism, 
HSPA9 is an essential component of inner mitochondrial membrane import and this 
process does not occur in its absense78,92,93. 
 
2.5.2. Protein folding, degradation and disaggregation 
Studies of the S. cerevisiae Ssc1p, an ortholog of HSPA9, have yielded useful insights 
into the function of HSPA9. In addition to mitochondrial import, HSPA9 is involved in the 
process of folding and refolding proteins in the mitochondria. Transformation of a 
temperature-sensitive SSC1 yeast mutant with plasmids expressing either wild-type or 
mutant Ssc1p was used to measure the ability of mutant Ssc1p to refold an engineered 
hybrid protein after translocation into the membrane99. The previously described hybrid 
protein was shown to be resistant to proteinase K digestion when properly refolded100. 
The mutant Ssc1p allowed translocation of the hybrid protein; however, the hybrid 
protein was sensitive to proteinase K digestion, indicating it was not refolded following 
translocation99. Proper refolding of newly imported proteins requires HSPA9 to recruit 
the help of the J protein DNAJA3 (also known as hTid1), which is not involved in 
mitochondrial import, and GRPEL1 as a nucleotide exchange factor63,101. Following ATP 
hydrolysis, HSPA9 releases the precursor protein to the HSP60/HSP10 complex to 
complete the folding process102-104. 
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Through additional studies of Ssc1p, HSPA9 has also been implicated in the 
degradation of misfolded proteins through its interactions with GRPEL1. By stabilizing 
misfolded or damaged proteins in an unfolded conformation, Ssc1p makes these 
proteins available to mitochondrial proteases105-107.  
 
Denaturation and aggregation of proteins can occur following cellular stress. HSPA9 has 
been implicated in disaggregation of these proteins as one method of protecting cells 
from stress101,108. Loss of Ssc1p was also shown to result in mitochondrial protein 
aggregation independent of its mitochondrial import and extra-mitochondrial functions109. 
 
2.6. Additional functions 
2.6.1. Centrosome duplication 
HSPA9 is a positive regulator of centrosome duplication75. Overexpression of HSPA9 
promotes centrosome re-duplication through its physical interactions with p53 and Mps1 
kinase (also known as TTK). HSPA9 modulates cell cycle progression by superactivating 
an initiator of centrosome duplication, Mps1, and disassociating p53, an inhibitor of 
duplication. HSPA9 is a target of Mps1 phosphorylation at threonine 62 and serine 65, 
which is necessary for its ability to superactivate Mps1 and creates a feedback loop that 
promotes centrosome duplication. During mid-late G1, HSPA9 associates with 
centrosomes in an Mps1-dependent manner and disassociates during mitosis110. As a 
cell cycle checkpoint mediator, p53 can induce G1-arrest, potentially through its 
interactions with the centrosome111. Through these interactions, HSPA9 has been 
implicated in the promotion of centrosome duplication. 
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2.6.2. Fe-S cluster transfer 
HSPA9 is the nearest homolog of the yeast protein Ssq1p, which is required for Fe-S 
cluster biosynthesis81,112. The highly homologous Ssc1p can rescue deficiencies of 
Ssq1p, indicating Ssc1p can play a role in Fe-S cluster biosynthesis, but is significantly 
less efficient than Ssq1p113. Ssq1p is thought to be responsible for the transfer of 
assembled Fe-S clusters to recipient apo-proteins114. In vivo function of Ssq1p was 
shown to be dependent on its ability to bind the LPPVK binding motif of the Fe-S cluster 
scaffold protein, Isu115. Biochemical assays have shown that HSPA9 can bind this 
LPPVK binding motif found on the human Fe-S cluster scaffold protein ISU1, providing 
additional evidence for a possible role of HSPA9 in Fe-S cluster biosynthesis116.  
 
2.6.3. HSPA9 in endo- and exocytosis 
Murine Hspa9 has been identified in lipid rafts of various mouse organs117. Investigating 
the heparan sulfate proteoglycan (HSPG)-dependent endocytic compartment confirmed 
the presence of Hspa9 in lipid rafts, as well as implicated it in the nonclathrin-, 
noncaveolin-dependent endocytic pathway74. Endocytosis of magnetic nanoparticles 
conjugated to HSPG-specific antibodies was inhibited by knockdown of HSPA9 by 
siRNA in HeLa cells. 
 
It was shown that HSPA9 interacts with fibroblast growth factor (FGF)-1 during late G1 of 
the cell cycle118,119. When FGF-1 binds to cell surface receptors or heparan sulfate on 
the cell surface, it is internalized by an endocytic pathway and translocated through the 
cytosol into the nucleus. This interaction was shown to be dependent on previously 
described tyrosine phosphorylation of HSPA9, and the authors postulated that due to 
cellular localization, HSPA9 influences FGF-1 availability to FGF receptors119-121. Given 
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the more recent discovery of HSPA9 in HSPG-dependent endocytosis, it stands to 
reason that it may be involved in uptake of FGF-1. 
 
Another study demonstrated the presence of HSPA9 on vesicles exocytosed from tumor 
cells exposed to the membrane attack complex (MAC), implicating a role for HSPA9 in 
protection from MAC-mediated lysis. The MAC consists of blood plasma proteins that 
induce lysis in invading pathogens by insertion into the plasma membrane, inducing 
intracellular signaling or physical damage122. It has been shown that some cells can 
escape MAC-induced lysis through exocytosis123. HSPA9 was initially found in the 
exocytic vesicles that shed the MAC from K562 cells, protecting them from lysis induced 
by MAC insertion into the plasma membrane124. Knockdown of HSPA9 in K562 cells led 
to the rapid lysis of these cells by induction of the MAC125. In contrast, addition of purified 
HSPA9 protein to the media could protect rabbit erythrocytes from MAC-mediated lysis. 
The precise role of HSPA9 in this process is unknown; however, it has been shown to 
bind two key plasmid membrane proteins involved in this process, C8 and C9, and may 
prevent the polymerization required for their function124.  
 
HSPA9 has also been observed to associate with the IL-1 receptor type I, independent 
of ligand binding. HSPA9 could be dissociated from the immunoprecipitated receptor 
complex by increasing concentrations of ATP, and loss of this interaction does not 
interfere with receptor activation of downstream kinases. For these reasons the authors 
speculated that HSPA9 might be involved in receptor internalization, rather than IL-1 
signal transduction126. 
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2.7. Additional HSPA9 protein interactions 
Sections 2.5 and 2.6 describe known and putative functions of HSPA9 in various cellular 
pathways, which include interactions with a variety of proteins; however, HSPA9 has been 
shown to bind a variety of proteins by co-immunoprecipitation or yeast 2-hybrid that are not 
mentioned above. Further studies are needed to understand the functional impact of the 
interactions listed below. 
 
2.7.1. p53 
As described in Section 2.6.1, HSPA9 has been shown to bind and inhibit p53. HSPA9 
binds to p53 in the C-terminal cytoplasmic sequestration domain of p53 (amino acid 
residues 312-352), and through this interaction p53 is sequestered in the cytoplasm, 
preventing its nuclear translocation127. The pleiotropic effects of p53 have led to 
speculation about the role of HSPA9 in modulating p53 and regulating apoptosis128. 
HSPA9 interacts with p53 through its ATPase domain (amino acid residues 253-282, 
see FIGURE 1.2)129,130. One study identified that HSPA9 binds p53 as a substrate 
protein in a purified protein system. In this study, they were not able to recapitulate 
previous reports of the ATPase domain interaction, potentially due to the lack of other 
proteins that may be required for this interaction131. One protein that may mediate this 
interaction is HSPA9’s J protein and cochaperone, DNAJA3, that was shown to bind p53 
during hypoxia-induced cellular stress132. 
 
2.7.2. VDAC1 voltage-dependent anion-selective channel & IP3R (inositol 1,4,5-
trisphosphate receptor) 
HSPA9 was initially shown to interact with VDAC by a yeast 2-hybrid assay133. In order 
to enter or leave the mitochondria, most metabolites, including the ATP/ADP required for 
oxidative phosphorylation and cations such as K+ and Ca2+ that regulate mitochondrial 
	   17	  
membrane potential, have to pass through a VDAC channel134. VDAC1 interacts with an 
endoplasmic reticulum Ca2+ release channel IP3R, promoting the transfer of Ca2+ 
between these organelles76. HSPA9 was shown to colocalize and coimmunoprecipitate 
with VDAC1 and the endoplasmic reticulum receptor IP3R. Furthermore, HSPA9 
overexpression protected cells from Ca2+ overload, a key event in apoptosis that induces 
the opening of the permeability transition pore in mitochondria. It was postulated that 
HSPA9 protects the mitochondria from Ca2+ overload by connecting the IP3 receptor and 
VDAC and reducing the cationic selectivity of the VDAC76,135.  
 
2.7.3. p66shc 
HSPA9 may protect cells from oxidative stress through its interaction with the key 
mediator of oxidative stress-induced apoptosis, p66shc (SHC1). p66shc was found in a 
protein complex with HSPA9 in the mitochondria by size exclusion chromatography and 
confirmed by co-immunoprecipitation. This interaction is disrupted when cells are treated 
with inducers of oxidative stress136. When unbound in the intermembrane space of 
mitochondria, p66shc can oxidize cytochrome c to produce H2O2 and induce apoptosis 
through opening of the mitochondrial permeability transition pore (MTP)137.  
Overexpression of p66shc enhances apoptotic response to oxidative stress and 
increases ROS levels in a variety of cell types. In contrast, loss of p66shc protects cells 
from oxidative stress, reducing apoptosis and ROS levels138-140. 
 
2.7.4. Parkin, DJ-1 and α-synuclein 
Three proteins associated with Parkinson’s disease (PD) have been shown to physically 
interact with HSPA9, the functional consequences of which are not well understood. 
Hspa9 can be co-immunoprecipitated with DJ-1, a protein linked to autosomal recessive 
forms of PD, in multiple cell types141-144. DJ-1 has a known role in protecting cells from 
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reactive oxygen species, and upon treatment of cells with H2O2, more DJ-1 can be found 
in association with HSPA9145. HSPA9 has also been identified as a binding partner of α-
synuclein and Parkin, other genes associated with PD, using isotope-coded affinity tags 
(ICAT) and mass spectometry of cellular models of PD143,146-150. Mutations in the gene 
encoding Parkin, PARK2, are the most common cause of autosomal recessive cases of 
PD150. The interaction between HSPA9 and Parkin was confirmed using co-
immunoprecipitation, and functional consequences of this interaction were further 
studied. In this study, knockdown of HSPA9 sensitized Hela cells to oxidative stress-
induced apoptosis, a phenotype that could be rescued by overexpression of Parkin150. α-
Synuclein protein aggregation is associated with neural degeneration, and missense 
mutations in the gene that encodes this protein, SNCA, have been associated with 
familial PD. Overexpression of HSPA9 protected rotenone-induced neurotoxicity and α-
synuclein protein aggregation146. HSPA9’s role in PD will be further discussed in Section 
2.9.1. 
 
2.7.5. Additional HSPA9 binding partners and possible mechanisms of signaling 
regulation 
As a chaperone protein, it is likely that HSPA9 binds many proteins without exerting 
functional consequences. The following studies have shown HSPA9 binds AKT and 
ERK2, as well as other proteins that influence signaling through these proteins. However, 
reports of these interactions vary between groups and are likely context-dependent. 
Additional studies are required to fully understand the functional consequences of these 
interactions. 
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2.7.5.1. AKT 
Immunoprecipitation of proteins using activated or inhibited AKT as bait revealed an 
interaction between AKT and HSPA9 in K562 cells151. In PC12 cells overexpression 
of HSPA9 was protective against glucose deprivation-mediated apoptosis by 
maintaining pro-survival signals through increased phosphorylation of ERK1/2 and 
AKT. However, this group was unable to repeat the previously described co-
immunoprecipitation of AKT and HSPA9 during glucose deprivation conditions in this 
cell type152. 
 
2.7.5.2. ERK 
In contrast to Yang et. al. (Section 2.7.5.1), another group observed a reduction in 
ERK2 phosphorylation in COS7 cells following HSPA9 overexpression153. This 
observation stemmed from an unbiased yeast two-hybrid screen of proteins that 
interact with HSPA9. As expected, this screen identified components of the TIM-
TOM complex that were already known to interact with HSPA9 for its mitochondrial 
matrix import function previously described in Section 2.5.1. Two novel HSPA9 
binding partners identified in this screen included mevalonate pyrophosphate 
decorboxylase (MPD) and NADH dehydrogenase. The interaction between HSPA9 
and MPD was confirmed by co-immunoprecipitation. Overexpression of HSPA9 
resulted in a reduction in ERK2 phosphorylation that was rescued when MPD was 
also overexpressed. From this data, it was proposed that HSPA9 regulates ERK2 
through its inhibition of the mevalonate pathway protein MPD. This study did not 
further characterize the interaction with NADH dehydrogenase128. 
 
Another protein associating ERK and HSPA9 is the receptor for hyaluronan mediated 
motility (RHAMM)154. HSPA9 and HSPA5 were both co-immunoprecipitated and 
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shown to co-localize with RHAMM during interphase but not mitosis. RHAMM can 
bind ERK1/2 and is thought to regulate its activity155. Additional studies are needed 
to confirm functional consequences of this interaction and whether the cytoplasmic 
staining pattern is truly specific to RHAMM localization. However, if this interaction is 
real, HSPA9 likely plays a role in microtubule stabilization and may alter ERK1/2 
signaling through its interaction with RHAMM. 
 
2.8. Overexpression of HSPA9 
2.8.1. Disease associations 
Overexpression of HSP70 family members is common in a variety of cancers and is 
often associated with poor prognosis59. Overexpression of HSPA9 has been shown to 
provide a cytoprotective effect against glucose deprivation, hypoxia and ROS 
accumulation, and results in increased proliferation and survival in cells and worms156-159. 
Like other HSP70 family members, this protection from cellular stresses acts as an 
important survival function of the cell that is often utilized by cancer cells. Increased 
HSPA9 expression has been described in colon, liver, brain, skin, and breast cancers160-
163. Retroviral overexpression of HSPA9 in MCF-7 cells injected into nude mice resulted 
in more rapid tumor formation than the control virus, as well as an increase in 
chemotaxic invasive response in a transwell assay compared to control constructs160. 
Additionally, HSPA9 overexpression is correlated with poor-survival in colorectal 
adenocarcinomas and melanoma tumor malignancy162,163.  
 
2.8.2. Genetic models 
The number of population doublings by normal human lung fibroblasts was dramatically 
increased by overexpression of HSPA9164. Expanding on this result, transgenic 
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overexpression of the C. elegans ortholog HSP-6 resulted in ~43% increase in worm life 
span159.  
 
2.9. Inactivation or loss of HSPA9 
2.9.1. Disease associations 
Although most commonly described as being overexpressed in various diseases, loss 
of HSPA9 is associated with neurodegenerative disorders.  
 
2.9.1.1. Parkinson’s Disease 
Mitochondrial dysfunction and increased accumulation of reactive oxygen species 
have been implicated in the pathology of Parkinson’s disease (PD), a 
neurodegenerative disorder142,165,166. As an essential mitochondrial protein, HSPA9 
expression, protein interactions, and sequence variants have been investigated in 
the context of PD. An unbiased comparison of mitochondrial proteins isolated from 
substantia nigra, an area of the brain affected by PD, revealed reduced levels of 
HSPA9 in samples from patients with PD compared to normal controls144. Another 
study of proteins differentially expressed in post-mortem brain tissue from PD 
patients at different stages of disease progression identified an association between 
a reduction in cytosolic HSPA9 levels and PD progression167. From these studies, it 
was not clear whether a reduction in HSPA9 levels was a marker for disease or a 
risk factor for disease development and progression.  
 
Two groups sought to identify genetic variants in HSPA9 that may be risk factors for 
the development of disease142,165. For each study, DNA was isolated from ~300 
patients with PD and ~300 age matched controls and evaluated for mutations 
associated with disease. In both studies, 4 single nucleotide polymorphisms in 
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HSPA9 that are found with high frequency in the general population showed no 
association with disease risk. However, 4 heterozygous single nucleotide variants 
were identified between the two cohorts, each identified in a single patient with PD. 
The second study expanded their analysis and screened 1008 PD patients and 1342 
population controls for 3 of these variants142. Only 1 of the variants was identified in 
additional patients at an allele frequency of 0.0069%, indicating HSPA9 variants are 
quite rare. However, further analysis of these disease-associated variants shows 
they occur in highly conserved regions with functional consequences. Two of the 
newly discovered variants, A476T and P509S, are located in the substrate-binding 
domain of HSPA9, while the R126W variant is in the ATPase domain. Functional 
studies of these variants utilized knockdown of HSPA9 in the dopaminergic cell line 
SH-SY5Y, which resulted in increased mitochondrial reactive oxygen species (ROS) 
production and reduced mitochondrial membrane potential. Overexpression of wild-
type HSPA9 can rescue these mitochondrial changes. However, overexpression of 
these disease-associated variants could not rescue mitochondria in these cells, 
indicating these variants have reduced function. Additionally, fibroblasts isolated from 
a patient with the A476T variant had altered mitochondrial morphology compared to 
fibroblasts from a sibling without the variant. Collectively, these studies indicate that 
although these disease-associated variants are rare, they have functional 
consequences that may contribute to PD pathogenesis.  
 
Other studies indicate that HSPA9 may also influence the development of PD 
through its interactions with three proteins associated with PD, Parkin, DJ-1 and α-
synuclein as described in Section 2.7.4. Taken together, these data indicate that 
loss of HSPA9 expression or function may contribute to PD pathogenesis or risk. 
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2.9.1.2. Alzheimer’s Disease 
HSPA9 has also been implicated in another neurodegenerative disorder, Alzheimer’s 
disease (AD). HSPA9 normally provides a cytoprotective effect in neuronal cells but 
may be functionally altered in AD patients.  
 
HSPA9 is involved in disaggregation of proteins, as discussed in Section 2.5.2. 
Aggregation of β-amyloid causes plaque formation and neurotoxicity in AD168,169. 
Hspa9 is up-regulated in response to β-amyloid in both PC12 cells overexpressing 
the amyloid precursor protein and in brains of P301L tau mice injected with β-
amyloid170,171. This upregulation may be a cytoprotective response to the β-amyloid 
accumulation since HSPA9 overexpression protected SH-SY5Y cells from β-amyloid 
induced toxicity172. 
 
HSPA9 is also altered by another protein associated with AD, ApoE, which may 
affect its ability to protect neuronal cells. ApoE variants are associated with 90% of 
AD cases in individuals under the age of 65173. Both HSPA9 isoform expression and 
phosphorylation were altered in an ApoE-driven mouse model of AD. These results 
were confirmed in AD patients with APOE variants, however, the significance of 
these changes are not well understood174. Loss of ApoE also results in a 10-fold 
increase in Hspa9 oxidation, potentially altering its function175.  
 
In summary, HSPA9 has been shown to have a cytoprotective effect in neuronal cells 
and loss of its function, regardless of mechanism, may contribute to neurodegenerative 
disorder pathology or risk.  
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2.9.2. Genetic models 
HSPA9 orthologs have been identified as essential genes in genetic models from yeast 
to zebrafish. TABLE 1.3 lists genetic models involving knockout or knockdown of known 
HSPA9 orthologs and their associated phenotypes. Collectively, unlike many HSP70 
family members, HSPA9 has an essential role in organismal development.  
 
2.10. Role in hematopoiesis 
Several HSP70 family members have been shown to influence hematopoiesis (recently 
reviewed in Mjahed et. al.). Hsp70 regulates Stat5 and Bcl-xl signaling in hematopoietic cells 
transformed with the BCR-ABL fusion gene and regulates erythropoiesis by protecting 
GATA-1 from caspase-3 mediated cleavage52,176. HSPA8 was previously shown to regulate 
the localization of cyclin D in hematopoietic stem cells, thereby controlling HSC 
quiescence177. Another HSP70 family member, the ER-specific HSPA5, was shown to 
regulate glycolytic metabolism and HSC self-renewal178. Collectively, the HSP70 family of 
proteins is involved in a wide variety of functions in hematopoiesis. It stands to reason that 
the highly expressed HSPA9 may also play a role in normal or malignant hematopoiesis. 
 
2.10.1. Zebrafish  
The earliest compelling data for HSPA9’s role in hematopoiesis came from Danio rerio. 
Analysis of a blood development mutant known as crimsonless (crs), initially identified in 
an ENU mutagenesis screen, revealed a single point mutation in a highly conserved 
residue within the nucleotide-binding domain of Hspa9. (FIGURE 1.2)179 In the 
homozygous state this mutation caused phenotypes characteristic of MDS: severe 
anemia, defects in erythroid differentiation, multilineage cytopenias, and increased 
apoptosis. Heterozygotes also showed increases in ROS accumulation. Evidence from 
other HSPA9 orthologs indicates that the point mutation observed in the zebrafish crs 
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mutant likely resulted in a hypomorphic allele. Mutations in the corresponding conserved 
amino acid of E. coli’s HSPA9 homolog, DnaK, results in a significant reduction in 
peptide binding61,180. In vitro biochemical analysis of human HSPA9 carrying this 
mutation disrupted its chaperoning ability by significantly reducing its affinity for J-protein 
co-chaperones involved in client protein recognition as well as the rate of nucleotide 
exchange following client protein recognition. This group also created a mutation in the 
corresponding location of the S. cerevisiae ortholog Ssc1, which resulted in a lethal 
phenotype63. Collectively, these data indicate that loss of normal Hspa9 function causes 
ineffective hematopoiesis in zebrafish and provide compelling evidence to study HSPA9 
in hematopoiesis. 
 
2.10.2. Erythropoietin signaling 
Analysis of erythropoietin (EPO)-dependent PI3K/AKT signaling in purified human 
erythroid colony forming cells identified HSPA9 as a target regulated by this pathway158. 
Increasing HSPA9 mRNA levels correlated with increasing levels of EPO. Investigation 
of signaling pathways downstream of EPO-R implicated that regulation of HSPA9 mRNA 
was downstream of the PI3K, and not the MAPK, signaling pathway. Furthermore, 
knockdown of HSPA9 by siRNA, like inhibition of PI3K signaling, inhibited cell grown in a 
human erythroid culture system. These results indicate that HSPA9 is both regulated by 
this indispensible erythroid-specific signaling pathway and is also involved in promoting 
erythropoiesis. 
 
2.10.3. CD34+ cell in vitro differentiation 
Human cord blood derived CD34+ cells were used to further evaluate the effects of 
HSPA9 knockdown in human hematopoiesis36. HSPA9 levels were reduced ~30-90% 
using 5 lentiviral shRNA knockdown constructs. These cells exhibited a dose-dependent 
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reduction in the percentage of cells in S-phase, decreased erythroid differentiation, and 
increased apoptosis; all common features observed in early-stage MDS. No disruption of 
megakaryocyte or myeloid differentiation was identified. Consistent with a reduction in 
erythroid differentiation, erythroid colonies grown in methylcellulose media were reduced 
in number and had reduced hemoglobin levels. The dose-dependent increase of 
apoptosis in HSPA9 knockdown cells was accompanied by increased caspase-3 
cleavage and increased mitochondrial depolarization, changes that were significant 
when HSPA9 levels were reduced by ~50%36. Collectively, these results support a role 
for HSPA9 in human erythropoiesis, which may contribute to the clinical features of MDS. 
 
2.10.4. Fe-S clusters in erythropoiesis 
As described in Section 2.6.2, HSPA9 has been implicated in iron sulfur cluster 
biosynthesis. Disruption of Fe-S cluster biosynthesis has been shown to disrupt 
mitochondrial iron metabolism and result in ineffective erythropoiesis181. Erythroid 
maturation is highly dependent on iron homeostasis due to the high demands of heme 
biosynthesis. Mutations in Fe-S cluster biosynthesis proteins GLRX5 and ABCB7 have 
been shown to cause ineffective erythropoiesis in model organisms and are associated 
with congenital sideroblastic anemia in humans182-186. If HSPA9 performs the same role 
as one of two yeast homologs, Ssq1p, its loss may alter erythropoiesis through this 
mechanism. 
 
2.10.5. Mouse knockdown 
Two groups have utilized shRNA knockdown of Hspa9 in murine bone marrow and 
described alterations of early hematopoietic cells in mice. 
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In 2010, Chen et. al. modeled Hspa9 loss in a murine bone marrow transduction/ 
transplantation model. Mouse bone marrow cells were transduced with lentiviral vectors 
co-expressing a YFP reporter and an Hspa9 shRNA or a control shRNA. These bone 
marrow cells were then transplanted into lethally irradiated congenic recipients. With this 
method ~50% knockdown was achieved in bone marrow and spleen cells. Hspa9 
shRNA recipient mice had reduced erythroid precursors and B cells with normal T cell, 
neutrophil, and monocyte populations in their bone marrow, spleen, and peripheral blood. 
A population of early progenitors (KLS cells) and megakaryocyte/erythrocyte progenitors 
(MEP) were also significantly reduced36. Collectively, the data suggests that loss of 
Hspa9 alters hematopoietic progenitors, leading to ineffective hematopoiesis, particularly 
erythropoiesis and B-cells, in mice. 
 
More recently, increased reactive oxygen species production was observed in 
hematopoietic stem cells (HSC) treated with a small molecule inhibitor of Hspa9 and 
other Hsp70 proteins, MKT-077187. This increase coincided with a decrease in HSC 
number, but not hematopoietic progenitor number, that could be partially rescued with 
the antioxidant N-acetyl-L-cysteine. Since MKT-077 has been shown to target other 
members of the HSP70 family with described HSC function, follow-up studies utilized 
shRNA knockdown constructs to reduce Hspa9 expression187. HSC numbers were 
greatly reduced after 10 days in culture compared to controls. Following this result, 
retrovirally transduced HSCs were sorted and 5000 GFP+ HSCs and 200,000 helper 
mononuclear cells were transplanted into lethally irradiated recipients to evaluate stem 
cell function in vivo. Bone marrow myeloid, T- and B-cell frequencies were normal 1 
month after transplant; however, HSC and mononuclear numbers were reduced and 
KLS cells in G0 were significantly reduced. Evaluation of mRNA expression of cell cycle 
and ROS-related genes identified alterations in cell cycle genes (increased c-myc and 
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decreased p21Cip1 and p57Kip2), as well as decreased genes associated with oxidative 
stress (sestrin2, Sod2, Foxo1, Prdm16). In contrast, overexpression of Hspa9 resulted in 
increased donor-derived HSCs. Further investigation of Hspa9’s role in modulating ROS 
in HSCs was performed in the context of a protein known to interact with Hspa9, DJ-1. 
DJ-1 was previously shown to interact with Hspa9 in neuronal cells and has a known 
role in protection from ROS generation as described in Section 2.7.4141,142,145. This study 
confirmed that DJ-1 could be immunoprecipitated by Hspa9 in a murine hematopoietic 
progenitor cell line (EML cells) and co-localizes with Hspa9 in mitochondria following 
H2O2. DJ-1-/- mice have a significant reduction in HSCs at 24 months of age and a 
significant increase in fluorescent ROS indicator, DCF-DA, in these cells. 
Overexpression of Hspa9 significantly increased the number of HSCs in culture, but 
could not reduce the ROS generation in DJ-1-/- HSCs, collectively indicating that DJ-1 is 
required for Hspa9 to reduce ROS generation187. 
 
2.10.6. Association with AML 
As described in Section 1.2.2.2, HSPA9 lies on chromosome 5 within a commonly 
deleted region associated with transformation from MDS to acute myeloid leukemia 
(AML). Hspa9 has also been associated with murine AML development. In two retroviral 
insertional mutagenesis screens, Hspa9 was identified as a common integration site in 
mice that develop AML188,189. Hspa9 mRNA levels were not increased in tumors 
containing insertions, consistent with inactivation and not overexpression of Hspa9.  
 
3. Conclusions 
HSPA9 is a member of the highly conserved HSP70 family of proteins. This nuclear-encoded 
mitochondrial HSP70 chaperone has a known role in mitochondrial protein import and folding, 
as well as a cytoplasmic role in centrosome duplication. However, due to its plethora of 
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identified protein interactions, it has a putative role in a variety of cellular functions including Ca+ 
homeostasis in the mitochondria, mitochondrial iron-sulfur cluster biosynthesis, apoptosis 
inhibition, and cell signaling. As with many anti-apoptotic proteins, it is often associated with up-
regulation in a variety of cancer cell types; however, loss of HSPA9 has also been associated 
with human disease. In humans, HSPA9 is located on the long arm of chromosome 5 in a 
commonly deleted region identified in myelodysplastic syndrome that is associated with 
transformation to acute myeloid leukemia. Supporting a role for HSPA9 in hematopoiesis, RNAi-
mediated knockdown alters erythroid differentiation of human CD34+ cells and stem and 
progenitor cells in mice. Finally, zebrafish with a functionally relevant point mutation have 
severe anemia and other hematopoietic alterations. Further understanding of HPA9’s role in 
hematopoiesis is key to understanding if its loss contributes to myelodysplastic syndrome and 
acute myeloid leukemia. Generation of a murine Hspa9 knockout model will provide a valuable 
tool to understand and study HSPA9’s functions in vivo. 
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Figure 1.1: Schematic of genes implicated in MDS and commonly deleted regions on 
chromosome 5 
Chromosome 5 is depicted with delineations of the two commonly deleted regions (CDRs) 
associated with MDS. TABLE 1.1 presents published data from genetic models supporting the 
role of candidate genes (depicted in blue) on 5q with MDS/AML. The proximal interval is 
associated with transformation to AML and all genes in this region are listed. This 2.5 megabase 
region contains 35 genes: 29 protein-coding genes, 5 non-coding RNAs (denoted with a *) and 
1 hypothetical gene (denoted with #). Genes in the proximal region are color coded based on a 
previously published gene expression array dataset of CD34+ cells from normal controls, MDS 
patients with del(5q) and non-del(5q) MDS patients26. Grey: hypothetical/pseudogenes and 
genes not detected in >70% of normal and MDS samples. Red: candidate genes that have 
significantly reduced mRNA levels in MDS patients with del(5q) compared to normal controls. 
Black: expressed in CD34+ cells but not significantly reduced in MDS patients with del(5q). 
 
Figure 1.2: Schematic of canonical HSP70 family member proteins as well as the HSPA9 
protein and locus 
A) Top: Predicted structure of HSP70 with ADP bound to the nucleotide binding domain (PDB 
code #2kho180). Bottom: HSP70 proteins consist of a highly conserved substrate binding domain 
(SBD, blue), linker domain (grey) and nucleotide binding domain (NBD, green). B) Unlike other 
HSP70 proteins, HSPA9 also has mitochondrial targeting sequence (MTS, red). The p53 
binding domain, known sites of phosphorylation (P, Thr62 and Ser65) and the homologous 
amino acid for the zebrafish point mutation (G498A) of HSPA9 are noted. C) HSPA9 has 17 
exons. The C/D box snoRNA SNORD63 lies within intron 10 of HSPA9.  
 
 
 
	   31	  
Figure 1.3: The ATP-dependent chaperone cycle of HSP70 proteins 
Top of figure: The substrate binding domain (SBD) of the HSP70 protein (red) exists in the open 
conformation when the nucleotide binding domain (NBD) is bound to ATP. 1) A J protein co-
chaperone (green) facilitates binding of the client protein (purple) to HSP70’s SBD. 2) Binding of 
the client protein causes a global conformational change, promoting hydrolysis of ATP. 3) ATP 
hydrolysis increases affinity of the client protein by closing the lid domain. 4) Binding of the 
nucleotide exchange factor (NEF; blue) promotes the exchange of ADP for ATP and release of 
the client protein.  
 
Figure 1.4: Import of precursor proteins into the mitochondrial matrix 
Precursor proteins (pink) are imported into the intermembrane space of mitochondria through 
the translocase of the outer membrane (TOM) complex. Precursor proteins with a positively 
charged N-terminal presequence (purple) are targeted to the presequence translocase of the 
inner membrane (TIM23 complex). Mitochondrial membrane potential begins precursor protein 
translocation by TIM23 but assembly of the presequence translocase-associated motor is 
required to complete precursor protein translocation. PAM16 recruits PAM18 and TIM44 is 
required for recruitment of HSPA9. PAM18 (green) acts as HSPA9’s J protein co-chaperone to 
facilitate ATP hydrolysis, increasing HSPA9’s (red) affinity for the incoming precursor protein. 
Finally, GRPEL1 (blue) acts as HSPA9’s nucleotide exchange factor facilitating release of the 
precursor protein and the exchange of ADP for ATP, resetting HSPA9.  
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Table 1.1: Hematopoietic phenotypes of genes on chromosome 5 implicated in 
MDS 
Distal CDR 
(5q33.1) Phenotype Citation 
RPS14 
Knockdown of RPS14 with shRNAs leads to a block in 
erythroid differentiation of human CD34+ hematopoietic 
progenitors 
32 
8 gene deletion, 
including RPS14 
Heterozygous mice lacking a region spanning Rps14 and 
seven other genes in the distal region have macrocytic 
anemia, erythroid dysplasia and reduced colony forming 
capacity of hematopoietic progenitors. Loss of p53 in these 
mice restored the colony forming capacity of hematopoietic 
progenitors.   
49 
miR-145/miR-
146a 
Retroviral-mediated overexpression of target sequences 
causing knockdown of miR-145 and miR-146a in murine 
transduction/transplantation model resulted in 
thrombocytosis, mild neutropenia, and megakaryocytic 
dysplasia 8 weeks post transplant. 
35 
SPARC Homozygous deletion in mice caused thrombocytopenia and impaired BFU-E formation. 50 
     
Proximal 
CDR (5q31.2) Phenotype Citation 
EGR1 
Egr1+/- mice do not exhibit differences in basal 
hematopoiesis, but do develop increased rates of T cell 
lymphomas and a myeloproliferative disorder following N-
ethyl-N-nitrosourea (ENU) mutagenesis 
30 
CTNNA1 
Epigenetic silencing of the residual, non-deleted CTNNA1 
allele was identified in high-risk MDS patients and AML 
patients with del(5q). Overexpression of CTNNA1 reduced 
proliferation and increased apoptosis of a human 
promyelocytic cell line that harbors del(5q). 
21 
     
Implicated 
genes not in 
a CDR 
Phenotype Citation 
APC 
Heterozygous knockout mice die of macrocytic anemia and 
have reduced myeloid colony forming ability and 
hematopoietic stem cells (HSCs) with reduced ability to 
reconstitute hematopoiesis. The APCmin allele is the result of 
a point mutation that causes a premature stop codon and 
these mice develop a cell-extrinsic MDS/MPD. Homozygous 
knockout results in rapid bone marrow failure with increased 
apoptosis and cell cycle entry of HSCs. 
34,47,48 
NPM1 
Heterozygous mice frequently develop myeloid and 
lymphoid malignancies. Knockout mice die embronically with 
reduced hematopoietic precursors and severe anemia. 
45,46 
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Table 1.2: HSPA9 homologs 
Species Common name Symbol Identity (%) 
H.sapiens Human HSPA9 Protein DNA 
vs. P.troglodytes Chimpanzee HSPA9 99.9 99.9 
vs. M.mulatta Rhesus monkey HSPA9 99.6 98.3 
vs. C.lupus Dog HSPA9 98.8 92.7 
vs. B.taurus Cow HSPA9 98.5 92.7 
vs. M.musculus Mouse Hspa9 98.4 90.3 
vs. R.norvegicus Rat Hspa9 97.8 90.4 
vs. G.gallus Chicken HSPA9 92.7 80.2 
vs. D.rerio Zebrafish hspa9 86.4 75.2 
vs. D.melanogaster Fruit Fly Hsc70-5 78.0 68.4 
vs. A.gambiae Mosquito AgaP_AGAP010876 80.9 67.9 
vs. C.elegans Worm hsp-6 77.3 67.2 
vs. S.cerevisiae Yeast SSC1 65.6 62.5 
vs. S.pombe Fission yeast ssc1 64.4 61.0 
vs. M.oryzae Rice blast fungus MGG_04191 66.1 61.6 
vs. N.crassa Bread mold NCU08693 67.7 61.3 
vs. A.thaliana Mouseear cress  MTHSC70-2 62.8 63.7 
vs. O.sativa Asian rice Os02g0774300 63.5 64.0 
vs. O.sativa Asian rice Os03g0113700 64.3 64.4 
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Table 1.3: Genetic models with knockdown or knockout of HSPA9 orthologs 
Species Ortholog Phenotype Citation 
Saccharomyces 
cerevisiae 
(yeast) 
SSC1 Essential for growth 190,191 
Drosophila 
melanogaster 
(fly) 
Hsc70-5 
Two large forward genetic screens observed 
lethality through RNAi-mediated knockdown 
or P-element mediated homozygous 
knockout. 
192,193 
Dugesia 
japonica 
(flatworm) 
Djmot 
siRNA-mediated knockdown results in loss 
of regenerative abilities and stem cell 
(neoblast) growth arrest leading to the death 
of the animal 
194 
Caenorhabditis 
elegans 
(nematode) 
hsp-6 
RNAi-mediated knockdown is embryonic 
lethal and in adult worms causes a progeria-
like (early aging) phenotype with a reduction 
in ATP levels and abnormal mitochondrial 
morphology. Expression levels of HSP-6 
also decreases with age. 
195-197 
Danio rerio 
(zebrafish) Hspa9b 
Homozygous point mutants are 
developmentally arrested before reaching 
the larvae stage, ~48 hpf. An independent 
retroviral insertional mutant resulted in 
developmental delays and death prior to 
5dpf and exhibited reduce fin regeneration 
after being cut due to a severe reduction in 
cell proliferation. 
179,198,
199 
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1. Abstract 
HSPA9 is a gene located in a commonly deleted region of chromosome 5 that is associated with 
myelodysplastic syndromes. To investigate the role of Hspa9 in mouse hematopoiesis, we 
created an Hspa9 knockout mouse model that reduces mRNA and protein levels of Hspa9 to 
50% of normal. Analysis of hematopoietic stem, progenitor and mature populations of 
heterozygous knockout mice revealed no significant differences when compared to wild-type 
littermates in vivo. However, an in vitro colony-forming assay revealed that Hspa9 heterozygous 
mice have a significant reduction in bone marrow B-cell progenitor colony forming ability. This 
reduction is hematopoietic cell-intrinsic. Enumeration of B-cell progenitor populations in vivo 
revealed no significant difference in Hspa9+/- mice compared to Hspa9+/+ littermates, suggesting 
a functional defect exists for Hspa9+/- B-cell progenitors in vitro. Homozygous knockout of 
Hspa9 is embryonic lethal prior to fetal liver development, preventing further studies of the 
effects of complete loss of Hspa9 on hematopoiesis. Collectively, these data indicate that 
heterozygous loss of Hspa9 in mice does not affect hematopoiesis in vivo, however, does cause 
a functional defect in B-cell progenitors in vitro. 
 
2. Introduction 
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell 
disorders characterized by ineffective hematopoiesis and accelerated apoptosis1,2. 
Approximately 30% of MDS patients will develop a highly chemotherapy-resistant form of acute 
myeloid leukemia (AML)3. Understanding initiating steps and the underlying mechanism of 
transformation may provide an avenue for therapeutic intervention.  
 
Heterozygous, interstitial deletions or loss of the long arm of chromosome 5 (5q) are among the 
most common acquired genetic abnormalities found in MDS2,4-6. Two commonly deleted regions 
(CDR) on chromosome 5 have been identified. Loss of the distal region, 5q33.1, is associated 
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with 5q minus syndrome, which carries a low risk for transformation to AML7-9. Loss of the 
proximal 5q31.2 region is correlated with a high-risk form of MDS and is associated with AML 
progression6,10-13. No mutations resulting in loss of both copies of genes in either CDR have 
been identified, implicating gene haploinsufficiency as a driver of disease6,12-15. In accordance 
with this, 7 of 28 genes in 5q31.2 were observed to have ~50% reduced mRNA levels in CD34+ 
cells from del(5q) MDS patients when compared to control samples12. One of these genes 
encodes for the chaperone protein HSPA9. An unbiased screen of the protein coding genes on 
this interval in a primary human erythroid culture system identified HSPA9 as the top candidate 
gene on this interval that likely contributes to disruption of erythroid maturation, a hallmark of 
MDS. 
 
The role of HSPA9 in hematopoiesis has been studied in multiple systems. Hspa9-/- zebrafish 
suffer from severe anemia and have defects in erythroid differentiation with increased apoptosis 
characteristic of MDS16. HSPA9 has also been implicated as a downstream mediator of 
erythropoietin signaling in a primary human CD34+ cell culture system17. Utilizing RNAi 
knockdown of HSPA9 in primary human CD34+ cells and a murine bone marrow transplant 
model, Chen et. al. showed that ~50% knockdown of this gene results in cell cycle alterations, 
disruption of erythroid differentiation, reduced proliferation, and increased apoptosis—all 
characteristics of MDS. A more recent study utilizing RNAi knockdown of Hspa9 in a murine 
bone marrow transplant model further characterized the consequences of Hspa9 reduction in 
hematopoietic stem cells (HSCs), including increased reactive oxygen species and a reduction 
in quiescent HSCs, both of which are associated with altered HSC function18-21. Several 
members of the highly conserved family of HSP70 proteins have been shown to be involved in 
hematopoiesis. These chaperone proteins have been shown to influence hematopoiesis through 
their roles in cell signaling, cell cycle and glycolytic metabolism22-26. The diverse known and 
putative roles of HSPA9 indicate that it is likely involved in many cellular processes, all which 
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could contribute to alterations in hematopoiesis. In addition to its putative role in MDS, Hspa9 
has been implicated in AML transformation. Hspa9 is associated with mouse AML in retroviral 
insertional mutagenesis screens and as a cooperating mutation in tumor suppressor-deficient 
mice that develop cancer (insertion leading to inactivation)27-29. These data support HSPA9 as a 
candidate gene that may contribute to abnormal hematopoiesis in MDS and development of 
AML. 
 
Previous studies have utilized RNAi-mediated methods to study HSPA9 in primary human and 
mouse cells. These methods are transient and while they lead to global knockdown, there is a 
high degree of variability for the level of knockdown on a per cell basis, and do not accurately 
model single copy loss of Hspa9 as seen in patients. Previous studies have also illustrated how 
sensitive cells are to Hspa9 levels, showing phenotypes of increasing severity inversely 
correlated with Hspa9 levels30. In order to improve upon existing models of Hspa9 loss of 
function and precisely model haploinsufficiency in a mammalian system, we created a 
heterozygous Hspa9 knockout mouse model. This model results in 50% loss of Hspa9 protein in 
all cells and was used to evaluate the effects of Hspa9 haploinsufficiency in murine 
hematopoiesis. 
 
3. Materials and Methods 
3.1. Embryonic stem cell clones 
Hspa9+/Gt(IST14901H6)TIGM mice (referred to as Hspa9+/-) were generated using C57Bl/6N 
Hspa9Gt(IST14901H6)TIGM embryonic stem (ES) cell clones provided by the Texas A&M Institute 
for Genomic Medicine. The ES cell clone library was created by random insertion of a 
retroviral gene trap vector containing a splice acceptor, a β-galactosidase/neomycin fusion 
reporter gene, and a poly-A tail, as previously described31. We identified an ES cell clone 
with a normal karyotype that harbored an insertion of the gene trap into intron 3 of Hspa9. 
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Confirmation of a single integration site was performed by Texas A&M using quantitative 
PCR for neomycin and inverse PCR for DNA adjacent to the insertion site, as previously 
described31,32.  
3.2. Mouse generation and colony maintenance 
C57Bl/6N-Hspa9Gt(IST14901H6)TIGM ES cells were injected into albino C57Bl/6J (C57BL/6J-Tyrc-
2J/J) blastocysts. Resulting chimeric progeny were bred to C57Bl/6N and produced viable 
Hspa9+/- pups. Mice were maintained on a C57Bl/6N background with the following 
exceptions, as noted in the text: C57Bl/6N x 129x1/SvJ F1 progeny for MOL4070LTR 
leukemogenesis studies, C57Bl/6N x FVB F1 progeny for BCR-ABL leukemogenesis 
studies, and C57Bl/6N x 129x1/SvJ mixed strain mice for embryonic lethality studies. Mouse 
procedures were performed according to protocols approved by the Washington University 
Animal Studies Committee.  
3.3. DNA extraction 
Tail DNA was extracted by phenol/chloroform extraction. Briefly, tails were incubated at 
55°C overnight in extraction buffer (25mM Tris pH 8.0, 25mM EDTA, 100mM NaCl, 1% 
Triton X-100) with 2mg/mL proteinase K (Sigma #2308). Protein and contaminants were 
removed by collection of the aqueous phase following the addition of phenol followed by the 
addition of chloroform. DNA was precipitated on ice by the addition of 100% ethanol and 
NaOAc (0.1M) followed by centrifugation. DNA pellets were washed with 100% ethanol to 
remove residual salt and left to dry. DNA was resuspended in TE buffer and used for 
southern blot or PCR genotyping. 
3.4. Southern Blot 
Southern blots were performed using standard methods. Briefly, 20µg tail DNA was digested 
overnight with XbaI. Digested DNA was precipitated by phenol-chloroform extraction as 
described above and resuspended 30µL TE followed by incubation at 37°C >1 hour to 
dissolve DNA. DNA was electrophoresed into 1% agarose gel overnight at 40V. The gel was 
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stained with ethidium bromide and photographed. DNA was depurinated by incubation with 
0.12M HCl for 10 minutes and denatured by incubation with 0.4M NaOH for 20 minutes. 
DNA was transferred to Hybond-XL membrane by capillary action overnight and rinsed with 
2xSSC buffer before drying. The membrane was exposed to 32P-labeled probe overnight at 
42°C. Following removal of the probe, the membrane was washed twice with 2xSSC buffer 
for 10 minutes at room temperature, twice with 2xSSC + 1% SDS at 65°C for 30 minutes 
and lastly 0.1xSSC for 30 minutes at room temperature. Finally, the bound probe was 
detected by autoradiography. The 300bp hybridization probe resulted in 4817bp fragment 
for a wild-type allele and 3303bp for a gene trap-containing allele (FIGURE 2.1 and 
2.2)(Probe sequence: TTTTTCCCCCCAGGATGGCTGGAATGGCCTTAGCCATGAGGCTT 
TTAGATTTGTTTCAAGAAGAGATTATGCGTAAGTACAACCTCAGTTTCTCTGAGAAAAAA
AAAAAAAACACTTATTGAACCTCAAAGCTTGGATGGGTTGGGTGCGTTATACATTTGTA
CTTGTAGTTTATTCAATATGCCACTGGTAACACCAACATAAAACACAGTTCTTCGTATTG
GAGACCACTGTTCAGATGACCATGGAATTTCATTTCTTACAGATCAGAAGCAATCAAGG
GTGCAGTGGTTGGTATTG). 
3.5. PCR genotyping 
Genotyping was performed as described by Zambrowicz 200331. An olignucleotide primer for 
the LTR of the gene trap (V76R, 5’-CCA ATA AAC CCT CTT GCA GTT GC-3’) and primers 
for regions flanking the gene trap insertion site (Forward, 5’-AGA CCA CTG TTC AGA TGA 
CCA TGG-3’; Reverse, 5’- TTA GAA GTC TGG AGC GGT CAA TGC-3’) as depicted in 
FIGURE 2.1 were used (synthesized by Sigma). This triple primer system results in a 453bp 
wild-type band and a 307bp band from the gene trap targeted allele. 50µL PCR reactions 
contained 50-100ng of tail DNA, 1.25 units of One Taq polymerase (NEB: M0480G), 1X One 
Taq standard reaction buffer with MgCl2, 0.3µM of each primer and 200µM dNTPs. PCR 
was performed as follows: initial denaturation at 95°C for 5 minutes, 40 cycles (95°C for 15 
seconds, 64°C for 1 minute, 72°C for 1 minute), and final extension at 72°C for 10 minutes. 
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PCR products (10uL) were electrophoresed on 2% agarose gel containing ethidium bromide 
using 100bp Ladder (NEB: N0467S) and 6x gel loading blue dye (NEB: B7021S). Typical 
results are shown in FIGURE 2.2.  
3.6. Western blot analysis 
3.6.1. Western blots 
Western blots were performed as previously described30. Cells were washed with PBS 
and pelleted before being resuspended in radioimmunoprecipitation (RIPA) buffer (150 
mM NaCl, 50 mM Tris [pH 8], 1 mM EDTA, 0.1%SDS, 0.5% sodium deoxycholate, 1% 
NP-40, 1 mM PMSF) with proteinase and phosphatase inhibitors (10mM NaF, 20mM 
NaPP, 1.25mM Na3VO4). Protein lysates were quantified using a standard BCA Protein 
Assay Kit (Pierce). Equal amounts of protein were loaded onto 4-12% gradient or 10% 
Tris-HCL gels and transferred to PVDF membranes according to standard protocols. 
Antibody detection was performed using SuperSignal West Pico Substrate (Thermo 
Scientific: 34077).  
3.6.2. Antibodies  
See TABLE 2.1. 
3.7. RT-PCR 
3.7.1. RNA preparation 
For preparation of whole bone marrow RNA, femurs were flushed with 1mL TRIzol 
Reagent (Invitrogen: 15596-018) using a 27 ½ gauge needle directly into microcentrifuge 
tubes. Alternatively, cells were sorted directly into TRIzol LS Reagent (Invitrogen: 10296-
028) or cell pellets were resuspended in 250µL molecular grade water and 750µL TRIzol 
LS Reagent was added, mixed well and stored at -80°C. RNA was processed according 
to manufacturer’s protocols. Briefly, 200µL chloroform was added, shaken vigorously, 
centrifuged at 12,000xg, and incubated at 4°C for 15 minutes. The aqueous phase was 
transferred to a fresh tube. 1µL of 15mg/mL RNase-free Glycogen (Invitrogen: AM9510) 
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was added as carrier followed by the addition of 500µL isopropanol. Samples were 
centrifuged at 12,000xg for 30 minutes at 4°C. Pellet was washed with 1000ul 75% 
ethanol and allowed to dry. RNA was resuspended in RNase-free water and incubated 
for 10 minutes at 55°C prior to storage at -80°C.  
3.7.2. Protein coding genes 
Genomic DNA was removed using TURBO DNA-free kit (Ambion AM#1907). cDNA was 
produced using SuperScript III First-Strand Synthesis System (Invitrogen: 18080-051) 
according to manufacturer’s protocols using oligo(dT)20 and random hexamer primers 
included in the kit. No reverse transcriptase (No RT) controls were processed in parallel. 
FAM-MGB primer/probe mixes for IL-6 (Mm00446190_m1), Flt-3L (Mm00442801_m1) 
and β-Actin (Mm00607939_s1) were used for RT-PCR TaqMan gene expression assays 
(Applied Biosystems, 4331182). Assays were performed as singleplex reactions 
according to manufacturer’s protocols using 60ng cDNA in 20µL reactions on a StepOne 
Plus Real time PCR System (Applied Biosystems). IL-7 and Gapdh RT-PCR assays 
were performed with SYBR Green using previously reported primers (IL-7 forward: 5′-
TCT GCT GCC TGT CAC ATC ATC-3’, IL-7 reverse: 5′-GGA CAT TGA ATT CTT CAC 
TGA TAT TCA-3’; Gapdh forward: 5’-TGC ACC ACC AAC TGC TTA G-3’, Gapdh 
reverse: 5’-GAT GCA GGG ATG ATG TTC-3’)33. IL-7 and Gapdh assays were 
performed as singleplex reactions according to manufacturer’s protocols using 40ng 
cDNA in 25µL reactions on a StepOne Plus Real time PCR System (Applied 
Biosystems). 
 
For analysis of Hspa9 mRNA expression, FAM-MGB Hspa9 (Mm00477716_g1) and 
Gapdh (Mm99999915_g1) were used. The RT-PCR was performed with Taqman 
Universal PCR master Mix No AmpErase UNG (AB#4324018, Applied Biosystems). The 
cycling conditions consist of incubation for 2 min at 50°C, followed by 95ºC for 10 min, 
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for denaturation followed by 40 cycles at 95ºC for 15 sec and combined annealing and 
extension at 60ºC for 1 min.  
 
All RT-PCR reactions were performed in duplicate with no-RT control on a StepOne Plus 
Real time PCR System (Applied Biosystems). Individual cDNA samples were normalized 
according to their levels of Gapdh transcript.  The relative standard curve method was 
used for analysis.   
3.7.3. snoRNA 
Amplification of snoRNAs from total RNA preparation was performed using TaqMan 
MicroRNA Reverse Transcription Kit (Applied Biosystems, 4366596) according to 
manufacturer’s protocols utilizing the included stem-loop primers. Custom ordered FAM-
NFQ primer/probe mixes were used for control snoRNA-202 (Context sequence: 5’-GCT 
GTA CTG ACT TGA TGA AAG TAC TTT TGA ACC CTT TTC CAT CTG ATG-3’), 
Gm26109 (Assay ID: CS5IOYS, context sequence: 5’-GCA TTT TAT TCA ACA CAT 
CAT TCT GAA AAT AGA TGT GTA GAG AAA TGA TAA CTG AGC ACA-3’) and 
Gm22200 (Assay ID: CS6RM40, context sequence: 5’-GAT GTA TTT GTC ACA TCA 
TTC TGA AGG AAA GTT TGT GGT GAC TTG TTA TTA CTG AGC ACA-3’) for RT-PCR 
TaqMan Small RNA Assay (Applied Biosystems, 4427975). The RT-PCR was performed 
with Taqman Universal PCR master Mix No AmpErase UNG (AB#4324018, Applied 
Biosystems). The cycling conditions consist of incubation for 2 min at 50°C, followed by 
95ºC for 10 min, for denaturation followed by 40 cycles at 95ºC for 15 sec and combined 
annealing and extension at 60ºC for 1 min.  
 
All RT-PCR reactions were performed in duplicate with no-RT control on a StepOne Plus 
Real time PCR System (Applied Biosystems). Individual cDNA samples were normalized 
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according to their levels of snoRNA-202.  The comparative Ct method was used for 
analysis. 
3.8. Cell counts 
Complete blood counts were performed by a Hemavet 950 hematology system (Drew 
Scientific). Enumeration of cell numbers for both primary cells and cell lines was performed 
by trypan blue exclusion with a hemocytometer by standard protocols or acridine 
orange/propidium iodide staining with a Cellometer Auto 2000 (Nexcelom) per 
manufacturer’s instructions. Red blood cell lysis was performed prior to enumeration of 
nucleated cells by incubation with 3% glacial acetic acid.   
3.9. Flow cytometry 
3.9.1. Cell preparation 
Bone marrow, spleen or peripheral blood cells were isolated by standard methods and 
red cells were lysed with ACK (Ammonium chloride potassium) lysis buffer (0.15M 
ammonium chloride, 10mM potassium bicarbonate, 0.1M EDTA). 
3.9.2. Antibodies 
See TABLE 2.2. 
3.10. Colony forming assays 
Bone marrow cells or splenocytes were harvested, red cell lysed with ACK buffer prior to 
being counted and plated in methylcellulose media per standard protocols. All 
methylcellulose media was purchased from Stem Cell Technologies (MethoCult Media). 
Bone marrow cells were plated as follows: 10,000 cells/plate for CFU-C/CFU-E/BFU-E 
formation (M3434), 100,000 cells/plate for mature BFU-E formation (M3234 supplemented 
with 3 or 6U/mL hEPO), 100,000 cells/plate for CFU-PreB (M3630). Splenocytes were 
plated in the same media as follows: 100,000 cells/plate for CFU-C/CFU-E/BFU-E formation, 
300,000 cells/plate for mature BFU-E formation. CFU-C and CFU-PreB colonies were 
scored on Day 7-10. BFU-E/mature BFU-E colonies were scored on Day 10-11. CFU-E 
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colonies were scored on Day 3. Benzidine staining of erythroid colonies was performed as 
follows: benzidine working solution was freshly prepared by mixing benzidine stock solution 
(30mg/mL benzidine in 90% glacial acetic acid) 1:1 with 21% H2O2, 400uL of working 
solution was added dropwise to methylcellulose plates, incubated 1-2 minutes and dark blue 
colonies were scored. 
3.11. Hematopoietic stress experiments 
3.11.1. 5-Fluorouracil 
A working stock of 10mg/mL 5-fluorouracil (5-FU, Sigma F6627) was prepared in sterile 
PBS and placed on a room temperature rocker overnight to fully dissolve in solution. The 
working stock of 5-FU was filtered through a 0.22µm filter prior to injection. Mice were 
weighed and injected with 150mg/kg 5-FU intraperitoneally weekly.  
3.11.2. Phenylhydrazine 
A working stock of 12mg/mL phenylhydrazine hydrochloride (PHZ, Sigma P6926) was 
prepared in sterile PBS and the pH of the solution was brought to an appropriate 
physiologic range (pH=7.4). The working stock of PHZ was protected from light prior to 
injection to prevent degradation. Mice were weighed and injected with 30mg/kg PHZ 
subcutaneously on Day 0 and Day 1. Mice were bled prior to first injection and every 2-3 
days during recovery.  
3.11.3. Sublethal irradiation 
Mice were bled prior to radiation for baseline measurements. On Day 0, mice were 
irradiated with 500 Rads and serial bleeds were performed weekly for 7 weeks to follow 
peripheral blood cell count recovery. 
3.12. HSPA9 overexpression 
3.12.1. Cloning 
HSPA9 cDNA was cloned from the previously described FLAG-Mortalin-WT vector into 
MSCV-IRES-GFP vector34. Briefly, primers (Forward: 5’-GTC ATG TAG GCT CGA GAT 
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CGA TTA CAA GGA TGA CGA TGA C-3’ and Reverse: 5’-GTC ATG TAG GCT CGA 
GTC TTC ACT CCT AAG CTT CAT ATG TTG TC-3’; synthesized by Sigma) were used 
to add XhoI restriction digest sites to the end of PCR fragments amplified from the 
FLAG-Mortalin-WT vector using iProof DNA polymerase kit (BioRad: 172-5301). PCR 
fragments were purified using the Wizard SV PCR Clean-up system (Promega: A9282). 
PCR fragments and MSCV-IRES-GFP were digested with XhoI at 37°C for two hours. 
Digested fragments were purified by Wizard SV PCR Clean-up system and gel 
quantified prior to ligation. Ligation of the PCR fragment and MSCV backbone was 
performed using the Takara DNA Ligation Kit V2.1 (Takara: Cat No 6022), transformed 
into DH5α cells using standard protocols and cultured overnight on Luria agar plates in 
the presence of 100µg/mL ampicillin. Individual colonies were picked and cultured in 
Luria broth for 8 hours before plasmid DNA was prepared using a QIAprep Spin 
Miniprep Kit (Qiagen: 27106). Plasmids were screened for the presence of HSPA9 
cDNA by XhoI restriction digest and orientation of the insert by EcoRI. Clones containing 
the HSPA9 cDNA insert in the correct orientation were sequence verified using standard 
Sanger sequencing.  
3.12.2. Viral preparation 
MSCV-IRES-GFP, MSCV-HSPA9-IRES-GFP and packaging plasmids were prepared by 
EndoFree Plasmid Maxi Kit (Qiagen: 12362). 60% confluent 150mm dishes of HEK293T 
cells were transfected with MSCV and EcoPack packaging plasmids by calcium 
phosphate transfection using CalPhos Mammalian Transfection Kit (Clontech: 631312) 
and viral supernatant was collected. Viral titer was evaluated by flow cytometry analysis 
of GFP expression in NIH3T3 cells 2 days after being spinfected with serial dilutions of 
each virus.  
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3.12.3. Bone marrow transduction/transplantation 
Bone marrow pools from either 3 Hspa9+/- or 3 Hspa9+/+ mice were transduced with 
either MSCV-IRES-GFP control or MSCV-HSPA9-IRES-GFP at an MOI of 1 in RPMI 
media containing 20% FBS, 50ng/mL mFlt3L, 100ng/mL mSCF, 60ng/mL mIL-3 and 
10ng/mL mTPO. Media was replaced following transduction and cells were cultured 
overnight. Cells were transduced again the following morning as described above, 
collected, and transplanted by injection of 100µL of cells in HBSS into the retro-orbital 
sinus of lethally irradiated recipients (1100Rads, 1 million cells/mouse). Remaining cells 
were cultured an additional day before transduction efficiency was evaluated by flow 
cytometry for GFP expression.  
3.13. Bone marrow transplantation 
Bone marrow was harvested from donor mice (Ly5.2), enumerated and pooled as 
necessary. Congenic recipients (Ly5.1) were lethally irradiated (1100Rads) 16-24 hours 
prior to transplant. 2 million non-RBC lysed cells were transplanted in 100uL DMEM with 
20% FBS or HBSS into the retro-orbital sinus. Transplanted mice were given 5mL antibiotics 
(200mg Sulfamethoxazole/40mg Trimethoprim) in a 400mL water supply for 2 weeks 
following transplant to prevent bacterial infection. For competitive repopulation studies, 
equal numbers of non-RBC lysed test (Ly5.2) and competitor (Ly5.1/5.2) marrow were 
mixed and 2 million cells per mouse were transplanted into lethally irradiated recipients 
(Ly5.1). 
3.14. GCSF treatment 
Anesthetized mice were subcutaneously injected with twice daily 125µg/kg doses of GCSF 
(Amgen) for 5 days. Mice were weighed immediately prior to first treatment. Mice were 
euthanized immediately following the last injection (Day 5) or at 2-day intervals thereafter. 
Competitive transplant mice were treated after establishment of long-term engraftment (>6 
months).  
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3.15. MOL4070LTR 
3.15.1. Virus production and titering 
MOL4070LTR infected NIH 3T3 cells (provided by Linda Wolff, NCI) were mixed at a 1:1 
ratio with uninfected NIH 3T3 cells, seeded on 100mm plates and allowed to grow to 
confluence in D10 media (DMEM containing 10% FBS, 2mM L-Glutamine, 100U/mL 
penicillin and 100ug/mL streptomycin). Media containing virus was collected the 
following day, filtered, and stored at -80°C until use. Viral titer was established using the 
XC cell assay, as previously described35.  
3.15.2. Viral injection and leukemic evaluation  
Hspa9+/- and wild-type littermate B6129F1 neonate pups (1-2 days old) were injected 
with 4*10^4 infectious particles in 0.1mL of D10 medium intraperitoneally. Mice were 
routinely observed for evidence of disease and sacrificed when moribund. CBCs were 
performed on peripheral blood using a Hemavet. Spleen and bone marrow cells were 
cryopreserved in 10% DMSO (20x106 cells/vial). Leukemias were classified according to 
Bethesda proposal methods36,37. Bone marrow or spleen cells were analyzed by flow 
cytometry for leukemic populations. For myeloid leukemias, cells were analyzed for the 
co-expression of immature (CD34, Sca, or c-kit) and mature (Gr-1 or CD11b) myeloid 
markers. For lymphoid leukemias, cells were analyzed for abnormal expression of B or T 
cell markers (B220, CD3, CD4 or CD8). Sections of spleen and liver, as well as thymus 
and lymph nodes when available, were fixed in 10% buffered formalin and sent for 
pathologic review by the Washington University Division of Comparative Medicine 
Research Animal Diagnostic Lab. Peripheral blood smears and cytospins of bone 
marrow and spleen cells were stained with Wright-Giemsa for morphologic analysis.  
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4. Results 
4.1. Generation of Hspa9+/- mice 
In order to evaluate Hspa9 haploinsufficiency in vivo, we created a mouse model with a 
heterozygous inactivation of Hspa9 (Hspa9+/-) using ES cells containing a gene trap inserted 
in intron 3 of Hspa9. Gene trap insertion was confirmed by Southern blot (FIGURE 2.2). 
Hspa9 protein levels were confirmed to be ~50% reduced in bone marrow and spleen cells 
by Western blot using both C-terminal and N-terminal antibodies (FIGURE 2.3). RT-PCR 
showed ~50% reduction in the mRNA level of Hspa9+/- compared to Hspa9+/+ littermates 
(FIGURE 2.3). 
 
Hspa9+/- mice are born at normal Mendelian ratios from Hspa9+/- x Hspa9+/+ matings (N>100) 
(TABLE 2.3). Intercrossing of Hspa9+/- mice did not result in the generation of homozygous 
mice (Hspa9-/-), suggesting that homozygous inactivation of Hspa9 is embryonic lethal 
(N=73) (TABLE 2.3). Background genetic differences due to mouse strain have previously 
been described to alter penetrance of embryonic lethality in some knockout mice38. In order 
to test whether the C57Bl/6 background of Hspa9+/- mice influenced lethality in Hspa9-/-, we 
crossed our C57Bl/6N Hspa9+/- mice with wild-type 129X1/SvJ mice (Jax: 000691) to 
generate Hspa9+/- B6129F1 mice. These heterozygous F1 mice were intercrossed and pups 
were genotyped (N=139) (TABLE 2.3). No Hspa9-/- pups were observed. Timed matings 
from Hspa9+/- x Hspa9+/- crosses failed to identify Hspa9-/- pups after 9.5dpc, preventing 
analysis of Hspa9-/- fetal livers (TABLE 2.4).  
 
4.2. Basal hematopoiesis is largely normal in Hspa9+/- mice up to 18 months of age 
Hspa9+/- mice and Hspa9+/+ littermates were evaluated at 2, 6, 9, 12 and 18 months of age. 
Hspa9+/- mice have normal complete blood counts, bone marrow and spleen cellularity, body 
weight and spleen size at all time points evaluated (FIGURE 2.4). Wright-Giemsa stained 
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peripheral blood smears as well as bone marrow and spleen cytospins evaluated for 
morphology appeared normal in Hspa9+/- mice (data not shown). Immunophenotyping of 
mature myeloid (neutrophils and monocytes), precursor and mature B-cells, mature T-cells, 
and mature and precursor erythroid cells (proerythroblasts, polychromatic erythroblasts, 
basophilic erythroblasts, reticulocytes) in the blood, bone marrow and spleen were normal 
(See TABLE 2.5 for immunophenotypic markers used) (FIGURE 2.5). The frequency of 
bone marrow hematopoietic progenitor (CMP, MEP, GMP) and stem-cell enriched (KLS, 
SLAM) populations were not significantly different up to 12 months of age (FIGURE 2.6). 
Consistent with our immunophenotypic analysis, bone marrow and spleen myeloid (CFU-C) 
and erythroid progenitors (mature BFU-E/BFU-E/CFU-E) evaluated by methylcellulose 
colony-forming assays were normal up to 18 months of age (FIGURE 2.7).  
 
4.3. Hspa9+/- mice did not exhibit altered recovery from hematopoietic stress 
Hspa9 has previously been shown to be up-regulated in response to a number of cellular 
stresses and provide a cytoprotective effect17,39-41. Although no overt phenotype was 
observed in hematopoietic stem and progenitor cells to affect myeloid and erythroid 
development in Hspa9+/- mice, these mice may be more sensitive to hematopoietic stress. 
To test this possibility, we induced hematopoietic stress in Hspa9+/- mice and their wild-type 
littermates with three methods: 5-fluorouracil, phenylhydrazine and sublethal irradiation. We 
utilized older mice (>5 months old) for these tests because they may be more susceptible to 
hematopoietic stress as evidenced by the late onset of MDS-like phenotypes in a variety of 
other mouse models42-44.  
 
4.3.1. 5-Fluorouracil 
5-fluorouracil (5-FU) is toxic to dividing cells and significantly reduces progenitor cell 
numbers in mice45. To evaluate survival following 5-FU treatment, we treated mice with 
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150mg/kg 5-FU weekly and sacrificed them when they become moribund. Mean survival 
was not significantly different between cohorts (15 days for Hspa9+/- and 17 days for 
Hspa9+/+, N=6/genotype, 6-8 months old) (FIGURE 2.8). 
 
4.3.2. Phenylhydrazine 
Phenylhydrazine induces hemolytic anemia in mice. In order to evaluate recovery of 
erythroid progenitors and precursors in mice >11 months of age, 30mg/kg 
phenylhydrazine was administered to Hspa9+/- and Hspa9+/+ littermate control mice. No 
difference in erythroid recovery was observed (FIGURE 2.8).  
 
4.3.3. Sublethal irradiation 
Finally, HSPA9 protein is highly up-regulated in several cellular stress inducing 
conditions, including following treatment with radiation46. To evaluate whether Hspa9 
was involved in recovery of hematopoietic cells following radiation, we irradiated 5-6 
month old mice with 500 Rads and monitored recovery of peripheral blood cell counts. 
There was no significant difference in standard complete blood count parameters 
following a single dose of sublethal radiation (N=5/genotype) (FIGURE 2.8).  
 
In summary, hematopoietic stress responses in Hspa9+/- and Hspa9+/+ littermates are not 
significantly different in response to 5-fluorouracil, phenylhydrazine and sublethal irradiation. 
 
4.4. CFU-PreB colonies are significantly reduced in Hspa9+/- mice 
As early as 2 months of age, the number of bone marrow CFU-preB methylcellulose 
colonies are significantly reduced in Hspa9+/- mice compared to Hspa9+/+ littermates (14 vs 
48 colonies/100,000 bone marrow cells plated, respectively, N=10 mice/genotype, 
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p<0.0001) (FIGURE 2.9). Splenic CFU-PreB colonies could not be evaluated due to the low 
frequency of B-cell progenitors in the spleen.  
 
To determine whether the CFU-PreB colony reduction was due to fewer progenitors added 
to the media, we used flow cytometry to evaluate the frequency of B-cell progenitors and 
precursors. There was no significant difference in number or frequency of common lymphoid 
progenitors (lin-/CD27+/flk2+/IL7Rα+/Ly6D-) or Hardy fractions A, B/C, D, E, or F in Hspa9+/- 
mice (N=5-10/genotype) (FIGURE 2.9). Ig light chain rearrangement is an essential process 
of normal B-cell differentiation. However, if normal B-cell differentiation is perturbed, the 
ratio of Igκ to Igλ chain usage could be altered47-49. No significant difference in Igκ or Igλ 
expression in 9-month old mice was detected (N=5/genotype) (FIGURE 2.9). 
 
4.5. The reduction in CFU-PreB colonies is partially rescued by HSPA9 
Two putative snoRNAs exist within introns 10 and 11 of Hspa9 that may contribute to the 
reduction in CFU-PreB colonies (FIGURE 2.1). Here we show that the gene trap insertion 
disrupts expression of the putative snoRNA, Gm26109, contained in intron 10 (FIGURE 
2.10). This snoRNA shares 83% identity with human SNORD63 located in intron 10 of 
HSPA9. The putative snoRNA Gm22200 contained within intron 11 could not be detected in 
whole bone marrow or B-cell progenitor subsets (CLP, Hardy fractions A-E) isolated from 
wild-type mice (data not shown). 
 
In order to show that loss of Hspa9 is responsible for the CFU-PreB colony reduction 
observed in these mice, we attempted to rescue this phenotype using an MSCV vector to 
overexpress HSPA9 in Hspa9+/- mouse bone marrow. Human HSPA9 cDNA was cloned into 
the MSCV-IRES-GFP expression vector (MSCV-IRES-HSPA9-GFP) and we achieved ~1.5 
fold HSPA9 protein overexpression in GFP+ NIH3T3 cells measured by densitometry 
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relative to MSCV-IRES-GFP vector (FIGURE 2.11). Bone marrow was harvested from 
Hspa9+/+ or Hspa9+/- mice and transduced with MSCV-IRES-GFP or MSCV-HSPA9-IRES-
GFP and transplanted into lethally irradiated recipients. GFP+ and GFP- cells were sorted 
from 8-10 week old mice and cultured separately in CFU-PreB methylcellulose medium 
(N=7-8mice/genotype, representative of 2 independent experiments). Colonies were scored 
7-days after plating. Untransduced (GFP-) cells from recipient mice yielded significantly 
fewer CFU-PreB colonies in recipients that received Hspa9+/- marrow than those that 
received Hspa9+/+ marrow, as expected. Transduction of Hspa9+/+ marrow with either the 
HSPA9 overexpression or control vector (GFP+ cells) did not significantly change the 
number of CFU-PreB colonies. However, Hspa9+/- bone marrow transduced with the HSPA9 
overexpression vector (GFP+ cells) significantly increased the number of CFU-PreB 
colonies produced by Hspa9+/- cells, while transduction of the control vector did not alter the 
number of colonies (p=0.015, Students t-test, N=7-8 mice/group) (FIGURE 2.11). 
Collectively, the data suggest that loss of Hspa9 expression contributes to the reduction in 
CFU-PreB colonies. 
 
4.6. The reduction of CFU-PreB colonies is hematopoietic-cell intrinsic 
In Hspa9+/- mice, one allele of Hspa9 is disrupted in all cells of the body, which could result 
in the contribution of non-hematopoietic cells to hematopoietic phenotypes. Stromal cells not 
derived from hematopoietic stem cells (HSCs) provide support to HSCs and hematopoietic 
progenitors and can specifically alter hematopoiesis when disrupted50-52. We tested whether 
the reduction in CFU-PreB colonies was a hematopoietic cell-intrinsic phenotype or due to a 
defect in non-hematopoietic stromal cells. We performed non-competitive bone marrow 
transplants of Hspa9+/- and Hspa9+/+ cells into wild-type or Hspa9+/- recipients. After long-
term engraftment was established (>6 months), we harvested bone marrow from recipient 
mice and performed the CFU-PreB assay. Results show that the reduction in B-cell 
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progenitors in Hspa9+/- mice is a transplantable, hematopoietic cell-intrinsic effect. The 
number of CFU-PreB colonies from mice that received Hspa9+/- bone marrow is significantly 
reduced compared to mice that received Hspa9+/+ bone marrow (N=7-9 mice/genotype, 
p=0.002). As expected, there was no reduction in CFU-PreB colonies following 
transplantation of wild-type donor bone marrow cells into Hspa9+/- recipients (N=5) (FIGURE 
2.12). Consistent with results from untransplanted mice, CLP frequencies were not 
significantly different between mice that received Hspa9+/- or Hspa9+/+ bone marrow 
following a non-competitive transplant (data not shown). 
 
4.7. Hspa9+/- B-cells do not have a competitive disadvantage at baseline or following 
stress 
Next, we tested whether Hspa9+/- lymphoid progenitors are at a functional disadvantage 
compared to progenitors from control mice in vivo by performing competitive repopulation 
studies. Pools of donor bone marrow from C57Bl/6 (Ly5.2) Hspa9+/- or Hspa9+/+ mice were 
mixed at a 1:1 ratio with a competitor bone marrow pool from age- and sex-matched wild-
type C57Bl/6 (Ly5.1) mice. There was no competitive advantage/disadvantage of Hspa9+/- 
cells compared to Hspa9+/+ cells in recipient mice at >6 months of age in 2 independent 
cohorts (N=3-8 mice) following primary or secondary transplants (FIGURE 2.13). Analysis of 
donor-derived B-cell precursors and progenitors following competitive transplant revealed no 
significant difference in the number or frequency of mature B-cells, CLPs, or Hardy fractions 
(FIGURE 2.14).  
 
We extended these studies to test whether Hspa9+/- B-cell progenitor recovery is abnormal 
following an acute, transient, decrease in bone marrow B-cells induced by granulocyte 
colony stimulating factor (GCSF). There was no detectable difference in recovery of B-cells 
progenitors or precursors following GCSF treatment in Hspa9+/- (N=2-5 mice/genotype) or 
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competitively transplanted mice (N=4-7/genotype) compared to wild-type controls (FIGURE 
2.14). 
 
4.8. Hspa9 haploinsufficiency alone does not induce MDS or leukemia in mice 
To determine whether heterozygous knockout of Hspa9 alone promotes AML, we monitored 
35 Hspa9+/- and 35 wild-type littermate mice for development of AML for 18 months. Hspa9+/- 
and control mice did not differ in overall or leukemia-free survival (FIGURE 2.15). 
 
4.9. Hspa9+/- mice are not more susceptible to leukemia induced by retroviral 
insertional mutagenesis 
In order to determine whether Hspa9 haploinsufficiency cooperates with additional 
mutations to cause leukemia, we used a well-established insertional mutagenesis model to 
induce leukemias35. Pure C57Bl/6 mice are less susceptible to virus-induced leukemias than 
B6129F1 hybrid mice. Therefore, Hspa9+/- mice were intercrossed with 129SvJ mice to 
create a cohort of B6129F1 mice, as previously described53,54. By injecting 45 
mice/genotype, we had 80% power to detect an increase in AML prevalence at one year 
from 20% in control to 50% in Hspa9+/- mice with a significance level (alpha) of 0.05 (two-
tailed) (GraphPad StatMate2). We injected 103 newborn mice (59 Hspa9+/-, 44 Hspa9+/+) 
with a Moloney murine leukemia-based virus (MOL4070LTR) and monitored mice for 
development of leukemia. MOL4070LTR induces both myeloid and T-cell leukemias that we 
characterized as described in the Methods (Section 3.15). We observed no difference in 
leukemia-free survival (all leukemias) (396 vs. 416 days, respectively, p=0.98) or AML-
specific leukemia-free survival (p=0.82). (FIGURE 2.16)  
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5. Discussion 
To evaluate the effects of Hspa9 haploinsufficiency on murine hematopoiesis, we generated a 
heterozygous knockout mouse from ES cells produced by Texas A&M with a gene trap 
insertion. Heterozygous mice have 50% less Hspa9 protein and mRNA than their wild-type 
counterparts and are born at normal Mendelian ratios. Consistent with other genetic models with 
homozygous knockout of Hspa9, Hspa9-/- mice are embryonic lethal. Lethality was prior to 
establishment of hematopoiesis in the fetal liver, preventing the use of Hspa9-/- fetal livers to 
study hematopoiesis in transplantation studies. Since genetic background has been shown to 
influence knockout phenotypes, including embryonic lethality as in the case of TGF-β1 mice55, 
we attempted to rescue this lethality by creating a mixed strain background of C57Bl/6N and 
129X1/SvJ. No Hspa9-/- mice were born as a result of this cross, indicating the C57Bl/6N 
genetic background is not required for embryonic lethality of Hspa9 homozygous knockout mice. 
 
We evaluated hematopoiesis in Hspa9+/- mice up to 18 months of age and identified a significant 
reduction in CFU-PreB colony formation as early as 2 months of age. We show this reduction is 
transplantable and a hematopoietic cell-intrinsic defect. This B-cell specific effect is consistent 
with our previous findings that lentiviral-mediated knockdown of Hspa9 resulted in a significant 
reduction in B220+ B-cells in bone marrow, peripheral blood and spleen of recipient mice. 
Unlike this model, however, we did not observe a reduction in the frequency of B220+ cells in 
Hspa9+/- mice compared to Hspa9+/+ mice. Further analysis of B-cell progenitor and precursor 
populations revealed no differences in frequencies between Hspa9+/- and Hspa9+/+ littermates. 
This indicates the reduction in CFU-PreB colonies is a functional defect and not a difference in 
the number of B-cell progenitors plated at the start of the assay. We also did not observe a 
reduction in B-cells derived from Hspa9+/- mice following competitive transplants, indicating that 
there is in vivo compensation for the cell-intrinsic defect in B-cell progenitors, which is further 
addressed in Chapter 3. Although not well studied, defects in B-cell progenitors have been 
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described in association with MDS. Reduced frequency and increased apoptosis of B-cell 
progenitors have been described and will be discussed in more detail in Chapter 356,57. Of note, 
the del(5q) abnormality has been described in CD19+ cells from patients with MDS, indicating 
haploinsufficiency of HSPA9 and other del(5q) genes could contribute to B-cell alterations.  
 
In addition to reducing Hspa9 expression levels, we have confirmed that the gene trap insertion 
disrupts expression of the snoRNA Gm26109, resulting in an ~30% reduction in expression 
(70% residual expression level). To our knowledge, this is the first time expression of this 
snoRNA has been measured in mice. However, we were unable to measure the expression of 
another putative snoRNA, Gm22200, located in intron 11 of Hspa9. The 70bp Gm26109 shares 
83% identity with the 68bp human C/D box small nucleolar RNA, SNORD63. The function of 
SNORD63 has not been experimentally demonstrated; however, one study predicted that 
SNORD63 was involved in the 2’-O-methylation of A4531 in 28S rRNA because of a 12-nt 
complementarity between these RNAs58. It is unclear what effect the reduced expression of this 
snoRNA has or whether it contributes to the reduction in CFU-PreB colonies. We were able to 
partially rescue the CFU-PreB phenotype by mild overexpression of human HSPA9 cDNA in 
mouse bone marrow by retroviral transduction; however, complete rescue was not observed. 
We chose mild overexpression (~2 fold in wild-type cells) in order to recapitulate wild-type levels 
to minimize bone marrow alterations, because overexpression of HSPA9 has been shown to 
provide a proliferative advantage in multiple cell types, including murine HSCs18,39,59. This 
incomplete rescue may be because HSPA9 expression was not high enough. However, 
additional lines of evidence indicate Gm26109 does not contribute to the CFU-PreB phenotype. 
In Chapter 3, shRNA-mediated knockdown of Hspa9 in mouse bone marrow results in 
significant reduction in B-cell progenitors without perturbation of Gm26109 expression. It is also 
very unlikely that the loss of SNORD63 is involved in hematopoietic defects described in 
zebrafish harboring mutations in hspa9b, the zebrafish homolog of HSPA9, because the only 
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predicted zebrafish homolog of SNORD63 (gene ID ENSDARG00000084148) is 56bp and only 
shares 54% identity with the human snoRNA. Additionally, this homolog is not located within 
hspa9b and is a predicted and not yet confirmed snoRNA. Therefore, it is unlikely to be effected 
in zebrafish knockout models of HSPA9. 
 
Heterozygous Hspa9 loss in zebrafish, and murine transduction/transplantation models 
evaluated by us and others, support a role for Hspa9 in erythroid development as well as stem 
and progenitor cell function16,18,30. Unexpectedly, we did not observe alterations in erythropoiesis 
or HSCs in Hspa9+/- mice. We propose three possible explanations. First, genetic loss of Hspa9 
throughout the entire lifespan of the animal may cause compensation in these mice, allowing for 
normal development. It remains to be seen whether acute heterozygous loss of Hspa9 in adult 
mice, as is seen in the context of human MDS, would results in additional hematopoietic 
defects. Second, heterozygous loss of Hspa9 may not be enough of a reduction to cause 
defects in mice. The alterations in HSCs, including increased cycling, increased reactive oxygen 
species and reduced number described by Tai-Nagara et. al., utilized 2 shRNA constructs that 
reduced Hspa9 expression to ~20% and ~35% of control constructs18. Chen et. al. utilized 
different shRNA constructs that reduced Hspa9 expression at the protein level to ~50% and 
~30% of controls30. We present data in Chapter 3 that indicates the previously described 50% 
reduction was likely closer to 40% the expression of controls. However, in both studies, these 
knockdown levels are the average of the entire cell population and the actual knockdown per 
cell is highly variable. A third explanation is that Hspa9 is not involved in murine erythropoiesis 
or HSC development, which is unlikely given the knockdown models utilizing 4 different shRNA 
constructs in assays performed by 2 independent groups.   
 
Patients with a deletion of the proximal 5q31.2 CDR are at a high risk of transformation to AML, 
indicating that del(5q) may be an initiating step in this process. Murine retroviral insertional 
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mutagenesis screens have identified Hspa9 as a common insertion site (CIS) in mice that 
develop AML and as a cooperating mutation in tumor suppressor-deficient mice that develop 
lymphomas27-29. Murine MDS and AML models often present hematopoietic alterations at 6-12 
months of age. Therefore, we evaluated murine hematopoiesis up to 18 months of age. 
However, no MDS or AML-like phenotypes were observed42-44,60. Leukemic development 
requires an accumulation of genetic and epigenetic alterations that provide a survival advantage 
for a cell. Del(5q) is thought to be an early event in MDS development and 5q31.2 is associated 
with increased transformation to AML61,62. In order to identify if loss of Hspa9 is an initiating step 
in this process, we induced additional mutations using retroviral insertional mutagenesis. The 
type and latency of leukemic development was not different in Hspa9+/- mice compared to 
Hspa9+/+ littermates, indicating Hspa9 may not be a gene on this interval associated with 
transformation. Conversely, a stronger cooperating gene, like TP53 mutations that are 
associated with del(5q)(Chapter 1, Section 1.2.2.1), may need to be used to sensitize this 
model. It is also likely that multiple genes on this interval cooperate to cause MDS as well as 
sensitize cells to leukemic transformation. Loss of Hspa9 may work in concert with loss of Egr1 
for this process. Mutagenesis induced by N-ethyl-N-nitrosourea showed heterozygous loss of 
Egr1 sensitized mice to T-cell lymphomas and myeloproliferative disorders. Therefore, future 
experiments designed to address the role of Hspa9 loss in the development of leukemia should 
focus on combinatorial approaches. 
 
In conclusion, we have generated a novel murine model with haploinsufficiency of the 5q31.2 
gene, Hspa9. These mice have a functional defect in B-cell progenitors but no other overt 
hematopoietic defects. Additional studies are needed to better understand how loss of Hspa9 
affects B-cells and whether this functional defect contributes to phenotypes observed in human 
MDS.  
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Figure 2.1: Southern blot confirmation and PCR genotyping of Hspa9+/Gt(IST14901H6)TIGM 
(Hspa9+/-) mice 
A) Southern blot of tail DNA digested with XbaI from 2 Hspa9+/+ and 2 Hspa9+/- mice showing a 
DNA fragment from a wild-type allele (white arrow, 4817 bp) and gene trap-disrupted allele 
(black arrow, 3303 bp). A Southern blot probe recognizing intron 1-exon 3, as depicted in 
Figure 2.2, was used. B) Results of 3 primer PCR amplification of tail DNA from 4 Hspa9+/+ and 
4 Hspa9+/- mice showing a band from the wild-type allele (white arrow, 453bp) and gene trap-
disrupted allele (black arrow, 307bp).  
 
Figure 2.2: Mouse Hspa9 locus with gene trap insertion 
A) 17 exons of the Hspa9 mouse locus on chromosome 18 with the location of the gene trap 
insertion depicted. Location of two putative snoRNAs, Gm26109 and Gm22200, in introns 10 
and 11 are indicated. Inset: Exons 1-4 of the Hspa9 locus with gene trap insertion. Locations of 
PCR genotyping primers (blue) and Southern blot probe (red) are indicated. B) Diagram of 
Hspa9 protein with regions targeted by N- and C-terminal Western blot antibodies indicated 
(black), p53 binding domain (light blue), known sites of phosphorylation (P), mitochondrial 
localization sequence (MTS, red) and canonical HSP70 domains (nucleotide binding domain, 
NBD; linker; substrate binding domain, SBD).  
 
Figure 2.3: Hspa9 expression is 50% reduced at the protein and mRNA level 
Western blots were used to evaluate Hspa9 protein expression in hematopoietic tissues from 
Hspa9+/+ and Hspa9+/- littermates. A) Expression of Hspa9 in bone marrow and spleen of 
littermates by C-terminal antibody and β-Actin loading control. B) Expression of Hspa9 in bone 
marrow of littermates by N-terminal antibody and β-Actin loading control. C) RT-PCR expression 
of Hspa9 mRNA in bone marrow of littermates (N=3/genotype). Statistical analysis by two tailed 
Student’s t-test. Error bars represent mean ± SD. 
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Figure 2.4: Organ cellularity, spleen size and CBCs are normal in Hspa9+/- mice 
A) No difference in total cellularity of bone marrow (left panel; 2 femurs, 2 tibias) and spleens 
(right panel) of Hspa9+/- (open circles) and Hspa9+/+ littermates (filled circles) at 2, 6, 9 and 12 
months of age. B) No difference in body weight (right panel), spleen weight (left panel) were 
observed. C) Peripheral blood complete blood counts were evaluated by Hemavet at 2, 6, 9, 12, 
and 18 months of age with no difference between genotypes. (PLT, platelets; MCV, mean 
corpuscular volume; Hb, hemoglobin; WBC, white blood cells)  
 
Figure 2.5: Immunophenotyping of bone marrow, peripheral blood and spleen cells up to 
12 months of age 
A) No difference was observed in red blood cell lysed bone marrow (left panel), peripheral blood 
(middle panel) and spleen (right panel) of Hspa9+/- and Hspa9+/+ littermates analyzed by flow 
cytometry for immunophenotypic markers for neutrophils (Gr1+/CD115-, red bars), monocytes 
(Gr1lo/CD115+, orange bars), B-cells (B220+, green bars) and T-cells (CD3e+, blue bars)(N=3-
6/genotype at each time point). B) Red blood cell precursors in bone marrow (left panel), 
peripheral blood (middle panel), and spleen (right panel) of Hspa9+/- (open circles) and Hspa9+/+ 
littermates (closed circles) at 12 months of age showing no difference in precursor frequencies 
between genotypes. Error bars represent mean ± SD. 
 
Figure 2.6: Progenitor and stem cell enriched populations are not altered in Hspa9+/- mice 
Bone marrow cells from Hspa9+/- (open circles) and wild-type littermates (filled circles) were 
collected, red blood cells lysed, and stained with immunophenotypic markers for A) KLS (cKit+, 
Lin-, Sca+), megakaryocyte-erythrocyte progenitors (MEP, Lin-Sca-cKit+FcγRloCD34-), 
granulocyte-monocyte progenitors (GMP, Lin-Sca-cKit+FcγRhiCD34+), common myeloid 
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progenitors (CMP, Lin-Sca-cKit+FcγRloCD34+) and B) SLAM (Lin-Sca+cKit+CD150+CD48-) cells 
(N=3-8 mice/genotype). Data from 12 month old mice is shown.  
 
Figure 2.7: Colony forming ability of erythroid and myeloid spleen and bone marrow 
progenitors from Hspa9+/- and Hspa9+/+ mice are similar 
Bone marrow or spleen cells were isolated from Hspa9+/+ (filled circles) and Hspa9+/- (open 
circles) littermates at 2-18 months of age. A) 10,000 bone marrow (left panel) or 100,000 spleen 
cells (right panel) were plated in CFU-C media and total colonies/plate were counted on day 7. 
B) 100,000 bone marrow (left panel) or 250,000 spleen cells (right panel) were plated in media 
containing only erythropoietin and mature BFU-E colonies were counted at 10-11 days. C) Cells 
from 18-month old mice were tested with different concentrations of erythropoietin added to the 
media (3 U/mL or 6 U/mL, as indicated). D) Bone marrow (left panel) or spleen cells (right 
panel) from 12-month old mice were plated in CFU-C media containing erythropoietin. BFU-E 
colonies were counted on day 10-11 and CFU-E colonies were counted on day 3 by benzidine 
staining. Statistical analysis by two tailed Student’s t-test. Error bars represent mean ± SD. (BM, 
bone marrow; Spl, spleen) 
 
Figure 2.8: Hspa9+/- and Hspa9+/+ littermate mice respond similarly to hematopoietic 
stress 
A) Kaplan-Meier curve of overall survival for Hspa9+/+ (solid line) and Hspa9+/- (dotted line) mice 
given weekly doses of 150mg/kg 5-fluorouracil (5-FU) is not different (mice aged 6-8 months, 
N=6 mice/genotype). B) Two doses of 30mg/kg phenylhydrazine (PHZ) was used to induce 
hemolytic anemia in Hspa9+/+ (black line) and Hspa9+/- (red line) mice. Mice were bled at 
indicated intervals to monitor for red blood cell recovery (N=5 mice/genotype) (hemoglobin (Hb), 
left; mean corpuscular volume (MCV), right). C) A single, sublethal dose of radiation (500 rads) 
was given to 5-6 month old Hspa9+/+ (black line) and Hspa9+/- (red line) mice and hematopoietic 
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recovery was monitored by complete blood counts at indicated time intervals (N=5 
mice/genotype) (white blood cell count (WBC), left; hemoglobin (Hb), right).  
 
Figure 2.9: Colony forming ability of B-cell progenitors is significantly reduced in 
Hspa9+/- compared to Hspa9+/+ mice 
A) CFU-PreB colonies were significantly reduced in Hspa9+/- (open circles) compared to 
Hspa9+/+ (filled circles) littermates at all times evaluated. Frequencies of B) Hardy fractions and 
C) common lymphoid progenitors (CLP) were not significantly different in Hspa9+/- mice at 4-5 
months of age. D) The distribution of Igκ and Igλ chain expression in 9-month old Hspa9+/- mice 
is normal. 
 
Figure 2.10: The gene trap insertion in Hspa9 disrupts expression of both Hspa9 and the 
snoRNA Gm26109 located in intron 10 of Hspa9 
RNA was harvested from bone marrow of 2-month old Hspa9+/+ (filled circles) and Hspa9+/- 
(open circles) littermates. qRT-PCR was performed on Hspa9 (left panel) and the putative 
snoRNA Gm26109 located in intron 10 of Hspa9 (right). Expression was calculated relative to 
Gapdh and sno202, respectively. Fold change was normalized to Hspa9+/+ control. Statistical 
analysis by two tailed Student’s t-test. Error bars represent mean ± SD.  
 
Figure 2.11: Overexpression of HSPA9 in Hspa9+/- bone marrow partially rescues the 
reduction in CFU-PreB colonies 
A) Western blot showing overexpression of HSPA9 cDNA in GFP+ sorted 293T cells 
transduced with MSCV-IRES-GFP control or HSPA9 overexpression vector (MSCV-HSPA9-
IRES-GFP). B) Bone marrow harvested from Hspa9+/+ or Hspa9+/- mice was transduced with 
MSCV-IRES-GFP control or MSCV-HSPA9-IRES-GFP and transplanted into lethally irradiated 
recipients. Bone marrow was harvested 8-10 weeks after transplant. GFP- (white bars) and 
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GFP+ (green bars) cells from each mouse were sorted and plated in CFU-PreB methylcellulose 
media. CFU-PreB colonies were counted on day 7. GFP+ and GFP- groups were analyzed by 
one-way ANOVA and a * indicates significantly different groups by post-hoc Tukey’s multiple 
comparison test, except for Students’ t-test for GFP+ versus GFP- in MSCV-HSPA9-IRES-GFP 
transduced Hspa9+/- colonies. Data includes two independently transduced and transplanted 
cohorts (N=7-8 mice/group).  
 
Figure 2.12: The reduction in CFU-PreB colony formation is hematopoietic cell-intrinsic 
A) Donor bone marrow from Hspa9+/- or wild-type mice was transplanted into lethally irradiated 
wild-type or Hspa9+/- recipients. Bone marrow was harvested 6 months after transplant and 
plated in CFU-PreB promoting methylcellulose (N=4-9 mice/genotype). B) Representative 
images of CFU-PreB colonies and individual cells following cytospin and Wright-Giemsa 
staining. (WT, wild-type, Hspa9+/+; HET, heterozygous, Hspa9+/-) 
 
Figure 2.13: Hspa9+/- bone marrow does not have a competitive advantage over control 
marrow in primary or secondary transplants 
A ratio of 1:1 Hspa9+/+ (blue lines) or Hspa9+/- (red lines) test cells (Ly5.2) and competitor bone 
marrow (Ly5.1/5.2) were transplanted into lethally irradiated recipients (Ly5.1). Mice were bled 
at intervals indicated after transplant and relative chimerism of peripheral blood (Panel A, solid 
lines) or B220+ cells (Panel B, dashed lines) were evaluated in primary recipients (left). 
Following long-term engraftment, bone marrow from recipients were pooled and transplanted 
into lethally irradiated secondary recipients (right). Secondary recipients were bled and 
evaluated for chimerism and times indicated. Bone marrow from secondary recipients was 
pooled and transplanted into tertiary recipients but showed no difference in chimerism between 
Hspa9+/+ and Hspa9+/- test marrow (data not shown). Data represents pooled results from two 
independently transplanted cohorts (N=10-15 mice/genotype). (Txp, transplant) 
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Figure 2.14: B-cell recovery is similar from Hspa9+/- and Hspa9+/+ bone marrow following 
GCSF treatment 
A) B-cell recovery in mice treated with GCSF twice daily for 5 days. Mice were sacrificed on 
days indicated and bone marrow B-cells were evaluated. No difference was observed in 
recovery of Hardy fractions A-F (data not shown). Representative results from B220+ cells are 
shown. B) Hspa9+/- (white bars) or Hspa9+/+ (grey bars) bone marrow (Ly5.2) was mixed at a 1:1 
ratio with competitor bone marrow (Ly5.1). Following long-term engraftment, frequencies of B-
cell progenitors from donor test marrow (Ly5.2) were measured. No differences were observed. 
C) A second cohort of competitively transplanted mice was treated with GCSF twice daily for 5 
days. Relative chimerism of B-cell progenitors was evaluated on day 11 and no differences 
were observed between genotypes. 
 
Figure 2.15: Overall and leukemia-free survival of Hspa9+/+ and Hspa9+/- mice are not 
different 
Kaplan-Meier plots showing no difference in A) overall and B) leukemia-free survival of Hspa9+/+ 
and Hspa9+/- littermates up to 18 months (N=35 mice/genotype). No difference was observed in 
mice followed up to 750 days (data not shown).  
 
Figure 2.16: Hspa9+/- mice are not more susceptible to leukemia induced by MOL4070LTR 
virus 
A) Overall survival of Hspa9+/+ and Hspa9+/- neonates injected with MOL4070LTR. B) The 
distribution of leukemia types evaluated in Hspa9+/+ and Hspa9+/- mice (mice sacrificed at 18 
months of age were excluded). C) AML-free survival of mice following MOL4070LTR injection. 
D) Representative peripheral blood smears showing AML (top) and ALL (bottom) blasts from 
Hspa9+/+ (left) and Hspa9+/- mice (right). 
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Table 2.1: Western blot antibodies 
Antibody Clone Vendor Catalog number 
Actin AC-15 Sigma A5441 
Hspa9 Polyclonal Abcam ab23854 
Hspa9 JG-1 Pierce MA3-028 
Stat5 3H7 Cell Sig Tech 9358 
pStat5 D47E7 Cell Sig Tech 4322 
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Table 2.2: Flow cytometry antibodies 
Antigen Fluorophore Clone Vendor Catalog number 
7AAD     Calbiochem 129935 
B220 (CD45R) APC RA3-6B2 eBioscience 17-0452 
B220 (CD45R) APCe780 RA3-6B2 eBioscience 47-0452 
B220 (CD45R) eFluor450 RA3-6B2 eBioscience 48-0452 
B220 (CD45R) FITC RA3-6B2 BD 533088 
B220 (CD45R) PE RA3-6B2 eBioscience 12-0452 
B220 (CD45R) PE-Cy7 RA3-6B2 eBioscience 25-0452 
B220 (CD45R) PerCP-Cy5.5 RA3-6B2 eBioscience 45-0452 
CD115 (c-fms) PE AF598 eBioscience 12-1152 
CD117 (c-Kit) APC 2B8 eBioscience 17-1171 
CD117 (c-Kit) APCe780 ACK2 eBioscience 47-1172 
CD11b APCe780 M1/70 eBioscience 27-0112 
CD11c PerCP-Cy5.5 N418 eBioscience 45-0114 
CD135 (Flt3/Flk2) APC A2F10 eBioscience 17-1351 
CD135 (Flt3/Flk2) PE A2F10 eBioscience 12-1351 
CD150 (SLAM) PE TC15-12F12.2 Biolegend 115903 
CD16/32 (FcΥ) eFluor450 93 eBioscience 48-0161 
CD16/32 (purified)   93 eBioscience 16-0161 
CD19 BV605 1D3 BD 563148 
CD19 PE-Cy7 eBio1D3 eBioscience 25-0193 
CD27 APC LG.7F9 eBioscience 17-0271 
CD34 PE RAM34 eBioscience 12-0341 
CD3e APC 145-2C11 eBioscience 17-0031 
CD3e eFluor450 17A2 eBioscience 48-0032 
CD3e FITC 145-2C11 BD 553062 
CD3e PE 145-2C11 eBioscience 12-0031 
CD3e PE-Cy7 145-2C11 eBioscience 25-0031 
CD3e PerCP-Cy5.5 145-2C11 eBioscience 45-0031 
CD4 FITC RM4-5 eBioscience 11-0042 
CD41 PE-Cy7 MWReg30 eBioscience 25-0411 
CD43 Biotin S7 BD 553269 
CD43 PE S7 BD 561857 
CD45.1 (Ly5.1) APC A20 eBioscience 17-0453 
CD45.1 (Ly5.1) PE-Cy7 A20 eBioscience 25-0453 
CD45.2 (Ly5.2) FITC 104 BD 553772 
CD45.2 (Ly5.2) PerCP-Cy5.5 104 BD 552950 
CD48 APC HM48-1 eBioscience 17-0481 
CD71 Alexa647 YTA74.4 ABD Serotec MCA1033A647 
CD8a (Ly-2) APC 53-6.7 eBioscience 47-0081 
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DAPI     Invitrogen D3571 
Gr-1 (Ly-6G) APC RB6-8C5 Caltag RM3005 
Gr-1 (Ly-6G) APCe780 RB6-8C5 eBioscience 47-5931 
Gr-1 (Ly-6G) FITC RB6-8C5 eBioscience 11-5931 
Gr-1 (Ly-6G) PacBlue RB6-8C5 Life Technologies RM3028 
Gr-1 (Ly-6G) PE RB6-8C5 eBioscience 12-5931 
Gr-1 (Ly-6G) PE-Cy7 RB6-8C5 eBioscience 25-5931 
IgD APC 11-26c eBioscience 17-5993 
IgD eFluor450 11-26c eBioscience 48-5993 
IgD PE 11-26c eBioscience 12-5993 
IgM APC II/41 BD 652032 
IgM eFluor450 eB121-15F9 eBioscience 48-5890 
IgM PE-Cy7 II/41 eBioscience 25-5790 
Igκ PE-Cy7 187.1 BD 560667 
Igλ FITC R26-46 BD 553434 
IL7Rα Biotin   **   
Ki67 FITC B56 BD 556026 
Ly6D Alexa647 49-H4 BD 561147 
Ly6D FITC 49-H4 BD 561148 
NK1.1 PerCP-Cy5.5 PK136 eBioscience 45-5941 
Sca-1 (Ly-6A/E) PE D7 eBioscience 12-5981 
Sca-1 (Ly-6A/E) PerCP-Cy5.5 D7 eBioscience 45-5981 
Stat5 (pY694) Alexa647 47/Stat5pY694 BD 612599 
Streptavidin 605NC   eBioscience 93-4317 
Streptavidin APCe780   eBioscience 47-4317 
Streptavidin eFluor450   eBioscience 48-4317 
Ter119 APCe780 TER119 eBioscience 47-5921 
Ter119 PE-Cy7 TER119 eBioscience 25-5921 
**Kindly provided by Deepta Bhattacharya 
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Table 2.3: Results of Hspa9+/- breeding indicate embryonic lethality 
Hspa9+/- x Hspa9+/+  
  Hspa9+/+ Hspa9+/- Total  
Males 59 83 142  
Females 62 57 119  
Total 121 140 261  
     
 Hspa9+/+ Hspa9+/-   
Expected ratio 1 1   
Observed ratio 1 1.16   
     
     
Hspa9+/- x Hspa9+/- 
  Hspa9+/+ Hspa9+/- Hspa9-/- Total 
Males 19 25 0 44 
Females 11 18 0 29 
Total 30 43 0** 73 
     
 Hspa9+/+ Hspa9+/- Hspa9-/-  
Expected ratio 1 2 1  
Observed ratio 1 1.43 0  
     
     
Hspa9+/- (B6129F1) x Hspa9+/- (B6129F1) 
  Hspa9+/+ Hspa9+/- Hspa9-/- Total 
Total 52 87 0** 139 
     
 Hspa9+/+ Hspa9+/- Hspa9-/-  
Expected ratio 1 2 1  
Observed ratio 1 1.67 0  
**p<0.0001, Chi-squared test (two-tailed)  
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Table 2.4: No Hspa9-/- embryos are found following fetal liver formation 
Embryonic Day Hspa9+/+ Hspa9+/- Hspa9-/- total # litters 
Day 9.5 2 5 0 7 1 
Day 11.5 3 2 0 5 1 
Day 12.5 4 7 0 11 2 
Day 13 3 4 0 7 1 
Day 14 3 2 0 5 2 
total 15 20 0 35 7 
      
Expected ratio 1 2.00 1   
Observed ratio 1 1.33 0   
      
      
Expected # 8.75 17.50 8.75   
Observed # 15 20 0*   
*p=0.001, Chi-squared test (two-tailed)   
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Table 2.5: Immunophenotypic markers 
Cell Type Cell type by 
description in text Flow cytometric markers 
B-cells B220+ 
Hardy Fraction A B220+CD3e-CD11c-NK1.1-IgM-IgD-CD19-CD43+LY6D+ 
Hardy Fraction BC B220+CD3e-CD11c-NK1.1-IgM-IgD-CD19+CD43+ 
Hardy Fraction D B220+CD3e-CD11c-NK1.1-IgM-IgD-CD19+CD43- 
Hardy Fraction E B220+CD3e-CD11c-NK1.1-IgM-IgD+ 
B-cell 
Hardy Fraction F B220+CD3e-CD11c-NK1.1-IgM+IgD+ 
proerythroblasts Ter119medCD71hi 
polychromatic 
erythroblasts Ter119
hiCD71hiFSCint 
basophilic 
erythroblasts Ter119
hiCD71hiFSChi 
Erythroid 
reticulocytes Ter119hiCD71loFSClo 
T-cell T-cells CD3e+ 
Neutrophils Gr1+CD115- Myeloid 
Monocytes Gr1+CD115+ 
Common lymphoid 
progenitor (CLP) B220-CD3e-Gr1-Ter119-CD27+Flk2+IL7Rα+Ly6D- 
Granulocyte-
monocyte progenitor 
(GMP) 
Lin-Sca-cKit+FcγRhiCD34+ 
Common myeloid 
progenitor (CMP) Lin-Sca-cKit+FcγR
loCD34+ 
Progenitor 
populations 
Megakaryocyte-
erythrocyte 
progenitor (MEP) 
Lin-Sca-cKit+FcγRloCD34- 
KLS Lin-Sca+cKit+ Stem-cell 
enriched 
populations SLAM Lin-Sca+cKit+CD150+CD48- 
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CHAPTER 3: 
The Role of Hspa9 in IL-7 Receptor Signaling 
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1. Abstract 
Heterozygous loss of Hspa9 in mice causes a significant, hematopoietic-cell intrinsic reduction 
in CFU-PreB colony formation in vitro. Gene expression profiling of CFU-PreB colony cells 
revealed significant down-regulation of B-cell signaling and activation pathway genes in Hspa9+/- 
compared to wild-type mice. Furthermore, knockdown of Hspa9 levels below 50% caused a 
significant reduction in B-cell progenitors in vivo without disrupting myeloid or T-cell lineages, 
further implicating Hspa9 in B-cell development. The addition of exogenous IL-7 to Hspa9+/- 
CFU-PreB cultures could partially rescue the reduction in colonies, without affecting Hspa9+/+ 
colonies, implicating Hspa9 in IL-7 receptor signaling. Hspa9 knockdown in an IL-7 dependent 
mouse proB-cell line resulted in a significant growth defect similar to that observed by reducing 
IL-7 concentrations in the culture media. Consistent with blunted IL-7 receptor signaling in 
Hspa9 knockdown cells, Stat5 phosphorylation was reduced in Hspa9 knockdown compared to 
control cells following IL-7 stimulation. Collectively, these results suggest that loss of Hspa9 
alters B-cell function by reducing IL-7-dependent Stat5 activation. 
 
2. Introduction 
The mitochondrial heat shock 70kDa protein, Hspa9, has roles in a variety of cellular processes 
and cell types. Loss of Hspa9 has been associated with reduced cellular proliferation and an 
increase in apoptosis in several genetic systems1-5. Previous work has illustrated how these 
alterations affect hematopoietic progenitors and particularly erythropoiesis in zebrafish, mouse 
and human cells2-4,6. A novel finding in an shRNA-mediated Hspa9 knockdown mouse model 
identified a reduction in B-cells (B220+), as well as erythroid cells (Ter119hiCD71+) in peripheral 
blood, bone marrow and spleen of mice3. This effect was erythroid and B-cell lineage specific as 
myeloid and T-cell lineages were unaffected. These results recapitulated phenotypes, such as 
anemia and other cytopenias resulting from ineffective hematopoiesis, observed in 
myelodysplastic syndrome (MDS), a clonal hematopoietic stem cell disorder. Up to 25% of 
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patients have an interstitial deletion or loss on the long arm of chromosome 5, where HSPA9 is 
located7. HSPA9 specifically lies within a 2.5 megabase commonly deleted region of 5q that is 
associated with poorer prognosis, implicating it in pathogenesis of this disease8-12.  
 
The previously described alterations in hematopoietic progenitors, erythropoiesis and mature B-
cells in models of Hspa9 loss support a role for HSPA9 in the pathogenesis of MDS. Anemia 
and effects on stem and progenitor populations are well described in MDS; however, alterations 
in B-cell populations have also been observed in MDS patients. B-cell progenitors 
(CD34+CD19+/-) are significantly reduced in low-risk MDS patients, and increased levels of 
apoptosis occur in CD19+ cells in MDS patients with RA, RARS and RAEB13,14. Engraftment of 
hematopoietic stem cells (HSCs) from patients with low-risk MDS resulted in significantly fewer 
donor-derived B-cells than normal HSCs15. Additionally, two B-cell signaling pathways were 
among the top 5 significantly down-regulated gene expression pathways in CD34+ cells from 
MDS patients (n=183) and del(5q) MDS patients (n=29) compared to 17 normal CD34+ bone 
marrow cells16. However, whether this is due to the loss of specific cell populations or altered B-
cell signaling is unclear. Another study showed that del(5q) also occurs in MDS patient bone 
marrow proB-cells (CD34+/CD19+), indicating B-cells can harbor del(5q) in MDS17. Although the 
literature on B-cells in MDS is limited, taken together, these results indicate that alterations in B-
cell populations exist in MDS patients, and early mouse data indicates that loss of HSPA9 may 
contribute to these alterations. 
 
In Chapter 2, we described a novel heterozygous knockout mouse used to investigate the role 
of Hspa9 in hematopoiesis. As early as 2 months of age, Hspa9+/- mice have a significant, 
hematopoietic cell-intrinsic reduction in CFU-PreB colony formation compared to Hspa9+/+ 
littermates. However, in vivo frequencies of B-cell progenitors are normal in Hspa9+/- mice when 
compared to Hspa9+/+ littermates at different ages, following a non-competitive or competitive 
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transplant. These results suggest that in vivo compensation may occur in mice to overcome the 
B-cell progenitor defect observed in vitro. In vivo, several cytokines are involved in B-cell 
proliferation and differentiation at different stages of B-cell development and may be involved in 
this compensation. However, IL-7 is the only exogenous cytokine added to CFU-PreB 
methylcellulose medium to promote colony formation suggesting it may be important in the 
phenotype. In order to investigate the role of Hspa9 on B-cell development and better 
understand the mechanism of in vivo compensation, we further investigated the role of Hspa9 in 
IL-7R signaling. 
 
3. Materials and Methods 
3.1. Colony forming assays 
CFU-PreB colonies were grown in methylcellulose medium containing 10ng/mL IL-7 (Stem 
Cell Technologies: M3630). Bone marrow cells were added at a concentration of 100,000 
cells/plate, in duplicate for each point reported. Exogenous IL-7 (Stem Cell Technologies: 
02577, 10ug/mL stock concentration) or Flt3-ligand (Peprotech: 50ug/mL stock 
concentration) was added to the media at various concentrations. The final concentration of 
IL-7 includes the 10ng/mL already present in the media (i.e., 90ng/mL was added for the 
reported 100ng/mL concentration). 
3.2. Microarray analysis 
To generate enough material for gene expression analysis, bone marrow was plated at 
250,000 cells/plate for Hspa9+/+ and 1x106 cells/plate for Hspa9+/- mice and replicate plates 
were pooled. Cells were isolated from CFU-PreB (Stem Cell Technologies: M3630) media 
on Day 7 by the addition of pre-warmed IMDM Media (Gibco: 12440046) with 20% FCS. 
Cells were washed with warmed media to remove remaining methylcellulose and cell 
surface stained. B220+ cells were sorted directly into TRIzol LS Reagent (Life Technologies: 
10296-028) using a Beckman Coulter MoFlo at the Washington University Siteman Flow 
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Cytometry Core. The Washington University Tissue Procurement Core performed RNA 
preparation and quantification. RNA was extracted from TRIzol LS using standard protocols. 
Total RNA quality and quantity was evaluated using the Eukaryote Total RNA Nano Series II 
(Agilent) assay on a 2100 bioanalyzer (Agilent). cDNA was prepared using the PicoSL 
Ovation system (NuGen). Samples were hybridized to Mouse Gene 1.0 ST arrays by the 
Washington University Biomedical Informatics Core. Gene-level normalization and signal 
summarization was performed for all arrays using Affymetrix Expression Console. 
Unsupervised hierarchical clustering using Ward’s, UPGMA, or WPGMA clustering 
algorithms with Euclidean distance were performed (Tibco Spotfire DecisionSite software). 
Differentially expressed individual genes were identified using Significance Analysis of 
Microarrays (SAM). Pathway analysis was performed on significantly altered genes using 
the Database for Annotation, Visualization, and Integrated Discovery (DAVID, 
http://david.abcc.ncifcrf.gov/).  
3.3. Cell culture 
B7 (Ba/F3 cells stably transduced with MSCV-mIL7R-IRES-GFP)18 cells were maintained at 
a density <2 million cells/mL in RPMI media with 10% FCS, 2mM L-glutamine, 100U/mL 
penicillin, 100ug/mL streptomycin and 10ng/mL mIL-7 (Peprotech: 217-17). HEK293T and 
NIH3T3 cells were maintained in DMEM with 10% FCS, 2mM L-glutamine, 100U/mL 
penicillin and 100ug/mL streptomycin. All cells were grown in a 37°C incubator with 5% 
atmospheric CO2. 
3.4. Flow Cytometry 
3.4.1. Cell cycle analysis 
Bone marrow cells were collected from 9-week old mice. 5 million cells/tube were 
incubated in 200µL FACS buffer (1mM EDTA, 2% FCS, PBS) for 10 minutes with 
purified anti-mouse CD16/32 to prevent non-specific binding. Cell surface staining (IgD, 
IgM, B220) was performed on ice, protected from light for 20 minutes. Cells were fixed 
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using BD Cytofix/Cytoperm solution (BD: 554714) for 15 minutes at room temperature. 
Cells were gently permeabilized with 2 washes in BD Fixation/Permeabilization solution 
before incubating with 5% goat serum (Sigma: G9023). Cells were stained with Ki67 for 
30 minutes on ice, washed and resuspended in FACS buffer containing DAPI prior to 
analysis. Cells were analyzed using a Gallios cytometer (BD Biosciences) and FlowJo 
software. 
3.4.2. Intracellular flow 
B7 cells were counted and collected by centrifugation at 90xg for 10 minutes. Cells were 
resuspended at a concentration of 20 million cells/mL in Nucleofector solution from the 
Amaxa Kit V per manufacturer’s instructions (Lonza: VCA-1003). Cells were 
electroporated with 1000nM Hspa9-targeting siRNAs (Thermo Scientific siGENOME 
Hspa9 siRNA D-057872-03 [siRNA 1] and D-057872-04 [siRNA 2]) or non-targeting 
control siRNA (Thermo Scientific siGenome Non-Targeting siRNA pool #2: D-001206-
14) using a Nucleofector Device (Lonza) program X-001. 500µL complete B7 media was 
immediately added to cells, which were transferred to culture plates containing B7 media 
for a final concentration of 1.3 million cells/mL. Cells were allowed to rest overnight in an 
incubator with 5% CO2 at 37°C before being counted and added to fresh media. Three 
days following electroporation, cells were collected, washed once with media lacking IL-
7, pelleted, and recultured in media without cytokines overnight. The next morning cells 
were stimulated with IL-7 at the described concentrations and collected. Media was 
removed and cells were resuspended in 500uL 2% paraformaldehyde. The time points 
indicated are from the addition of IL-7 to the resuspension in the 2% paraformaldehyde 
fixation solution. Cells were incubated at 37°C for 10 minutes and washed with 1mL 
PBS. Cells were pelleted and resuspended in 300µL ice-cold, 100% methanol and 
incubated on ice for 30 minutes for permeabilization. Cells were washed first with 1mL 
PBS, then with 1mL FACS buffer. pStat5 master mix was made by adding 10uL pStat5-
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Alexa 647 (BD Bioscience: 612599) per 100uL FACS. Cells were resuspended in 100uL 
pStat5 master mix and incubated at room temperature for 30 minutes, then cells were 
washed with FACS buffer and analyzed by FACScan (BD biosciences) using FlowJo 
software. 
3.5. Western blot analysis 
3.5.1. Standard Western blots 
Western blots were performed as previously described3. Cells were washed with PBS 
and pelleted before being resuspended in radioimmunoprecipitation (RIPA) buffer (150 
mM NaCl, 50 mM Tris [pH 8], 1 mM EDTA, 0.1%SDS, 0.5% sodium deoxycholate, 1% 
NP-40, 1 mM PMSF) with proteinase and phosphatase inhibitors (10mM NaF, 20mM 
NaPP, 1.25mM Na3VO4). Protein lysates were quantified using a standard BCA Protein 
Assay Kit (Pierce). Equal amounts of protein were loaded onto 4-20% gradient or 10% 
Bis-Tris gels and transferred to PVDF membranes according to standard protocols. 
Antibody detection was performed using SuperSignal West Pico Substrate (Thermo 
Scientific: 34077).  
3.5.2. Phosphorylated protein Western blots 
Western blots for phosphorylated proteins were performed as previously described19. 
Briefly, cells were either sorted directly into trichloracetic acid (TCA, Sigma: T0699) or 
suspended in water and the final concentration of TCA was adjusted to be 10% v/v. 
Extracts were centrifuged at 13,200 rpm for 10 minutes at 4°C. Pellets were washed 
twice with acetone and dried at room temperature. Pellets were solubilized in 1% 
dithiothreitol, 9M urea, and 2% Triton X-100 and 4X LDS sample buffer was added 
(Invitrogen: NP0008) before lysates were incubated for 10 minutes at 70°C. Samples 
were run on Novex 4-12% gradient Bis-Tris gels (Invitrogen: NP0321) and transferred to 
PVDF membranes (Millipore). Antibody detection was performed using SuperSignal 
West Femto Substrate (Thermo Scientific: 34095). Membranes were stripped by 
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incubation with a stripping buffer consisting of 25mM glycine, pH 2, and 1% sodium 
dodecyl sulfate for 30 minutes at room temperature, with agitation. 
3.6. Hspa9 knockdown studies 
3.6.1. Virus generation and titer 
Previously described Fcy-si control (shLUC) or Hspa9 knockdown (shHspa9 #3) vector 
plasmids were co-transfected into HEK293T cells with the packaging plasmids pMD-
LgpRRE (containing HIV gag/pol), pCMV-G (containing VSV-G), and RSV-Rev 
(containing Rev) by the Washington University HOPE Center viral vectors core3. Hspa9 
shRNAs are composed of a 21 or 23bp sequence (shLUC: 5’-GGT AGC GAC TAA ACA 
CAT CAA-3’; shHspa9 #3: 5’-GGG AGG CGT CTT TAC CAA ACT TA-3’) and a 9bp loop 
(ttcaagaga) followed by the reverse complement 21 or 23bp sequence. Viral titers were 
evaluated by transduction of NIH3T3 cells followed by flow cytometric measurement of 
the percentage of YFP+ cells on a FACScan flow cytometer (BD biosciences) with 
FlowJo software. 
3.6.2. Bone marrow transduction and transplantation 
Bone marrow was harvested from 10 C57Bl/6 (Ly5.2) mice and pooled. Cells were 
stained with biotinylated antibodies against CD3e, B220, Ter119 and Gr-1 
(eBiosciences) for lineage-depletion by AutoMACS column (Milteny Biotech) using anti-
Biotin beads (Milteny Biotech: 130-90-485). Lineage-depleted bone marrow was plated 
in 6-well plates at a density of 4 million cells/well in α-MEM media containing 15% FCS, 
50ng/mL mFlt3, 100ng/mL mSCF, 10ng/mL mIL-3, 10ng/mL mTPO (Peprotech) and 
penicillin/streptomycin. Cells were transduced once with an MOI of 20 by spinning for 90 
minutes at 2500rpm in the presence of 4µg/mL polybrene (American Bioanalytical: 
AB01643-00001) and 25mM HEPES buffer (Gibco: 15630-106). The following day, cells 
were pooled, counted and 0.75-1x106 cells were transplanted into the retro-orbital sinus 
of lethally irradiated (1100Rads) recipients (Ly5.1). 
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3.6.3. Colony formation 
YFP+ cells were sorted from recipients that received control (shLUC) or Hspa9-
knockdown (shHspa9 #3) transduced bone marrow using an iCyt Synergy flow sorter 
(Sony). 100,000 cells were plated in CFU-PreB methylcellulose media (Stem Cell 
Technologies, M3630), in duplicate.  
3.6.4. Flow cytometery 
Peripheral blood, bone marrow and spleen cells were isolated and red blood cells were 
lysed as described in Chapter 2, Section 3.9. Hardy fractions and other lineage markers 
were labeled and analyzed by immunophenotypic markers detailed in TABLE 2.5 using 
a Gallios or FACScan flow cytometer (BD Biosciences) and FlowJo Software.  
3.7. BCR/ABL transplantation 
3.7.1. Virus production 
HEK293T cells were transfected with 48µg MSCV-p210-BCR/ABL-IRES-GFP vector20 
and 24µg EcoPAC packaging vector by calcium phosphate transfection using the 
CalPhos Mammalian Trasfection Kit (Clontech: 631312). Viral supernatant was collected 
48 and 72 hours later. Viral titer was evaluated by calculating the percentage of GFP+ 
cells per volume of virus added by flow cytometry of NIH3T3 cells transduced with the 
virus using a FACScan (BD Biosciences) and FlowJo software. 
3.7.2. Transplantation 
C57Bl/6 Hspa9+/- mice were crossed with wild-type FVB mice. F1 Hspa9+/- or Hspa9+/+ 
progeny were used as donors and Hspa9+/+ F1 mice as recipients. Bone marrow from 3 
Hspa9+/+ or 3 Hspa9+/- mice was pooled and plated at 5 million cells/mL in RPMI with 
10% FCS. Cells were transduced once with an MOI of 0.1 by spinning for 90 minutes at 
1000xg in the presence of 8µg/mL polybrene (American Bioanalytical: AB01643-00001) 
and 10mM HEPES buffer (Gibco: 15630-106). Bone marrow was rested for 1 hour at 
37°C. Lethally irradiated recipients (1100 Rads) were transplanted by tail vein injection 
	   115	  
with 1x105 transduced cells and 1x106 untransduced wild-type helper total bone marrow 
cells in 200µL PBS. Mice were sacrificed when moribund and bone marrow and spleen 
cells were cryopreserved. 
 
4. Results 
4.1. The expression of B-cell proliferation and activation genes is reduced in Hspa9+/- 
CFU-PreB colonies  
To investigate whether a functional defect in downstream IL-7R signaling contributes to the 
reduction in CFU-PreB colonies in Hspa9+/- mice, we performed gene expression array 
profiling on colonies produced by Hspa9+/- and compared them to wild-type colonies. Day 7 
colonies were collected from methylcellulose and sorted for B220+ cells (N=5 
mice/genotype) (FIGURE 3.1). Analysis of mRNA expression levels revealed no global 
alterations as illustrated by the arrays not segregating by genotype in unsupervised 
hierarchical clustering. However, we identified small changes between Hspa9+/- and wild-
type colonies. Of the ~15,000 genes analyzed, 242 were significantly down-regulated and 
169 were significantly up-regulated in Hspa9+/- compared to controls. Hspa9 expression was 
reduced by 50% in Hspa9+/- versus Hspa9+/+ mice, as expected (FIGURE 3.1). When 
pathway analysis was performed on these genes using DAVID, we identified high 
enrichment scores (>3 fold enrichment) in pathways that promote lymphocyte proliferation 
and activation but no pathway enrichment in up-regulated genes (>1.5 fold enrichment) 
(TABLE 3.1). These results suggest that the reduction in CFU-PreB colonies may be due to 
blunted signaling in vitro. Nonetheless, it suggests that in vivo compensation may overcome 
the alterations seen in vitro, perhaps by increased cytokine production. Results of this assay 
were limited because it queried only the small number of cells that survived to Day 7 in 
CFU-PreB culture. Day 7 colonies consist of cells that have proliferated and differentiated 
from B-cell progenitors. Therefore, critical and potentially larger gene expression changes 
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may have been missed in populations that were more immature or died prior to this time 
point. 
 
To further investigate B-cell proliferation in vivo we stained whole bone marrow for B-cell 
and proliferation markers. Bone marrow from 9-week old mice showed no significant 
difference in cell cycle distribution by Ki67 and DAPI staining in Hardy Fractions E, F or 
combined early fractions A-D (N=5 mice/genotype) (FIGURE 3.2).   
 
4.2. IL-7, but not Flt3-ligand, partially rescues the CFU-PreB phenotype 
IL-7, Flt3-ligand, and SCF cytokine signaling drive early B-cell maturation in vivo21-23. To test 
whether increasing levels of cytokines in vitro could rescue the CFU-PreB phenotype, we 
added increasing concentrations of IL-7 in the media and observed a dose-dependent 
increase in Hspa9+/- colonies compared to no increase in Hspa9+/+ colony numbers (fold 
change in colony formation from 10ng/mL to 50ng/mL IL-7 was 1.80 for Hspa9+/- vs. 0.80 for 
Hspa9+/+, p=0.01 by one-way ANOVA, N=6 mice/genotype) (FIGURE 3.3). Supplementation 
of the media with Flt3 ligand did not alter Hspa9+/- or Hspa9+/+ CFU-preB colony formation, 
further implicating altered IL-7R signaling in the reduced CFU-PreB colonies (FIGURE 3.3). 
 
To ensure that this dose-dependent increase was not due to differences in IL-7 receptor 
expression, we evaluated IL-7Rα cell surface expression by flow cytometry. No significant 
difference in frequency or geometric mean was identified in Hardy fractions A-D in Hspa9+/- 
vs Hspa9+/+ mice (N=5/genotype)(data not shown). 
 
We also investigated IL-7 expression in the bone marrow of Hspa9+/- vs Hspa9+/+ mice to 
determine if heterozygous mice overexpressed B-cell promoting cytokines as a mechanism 
of compensation. Femurs were flushed with Trizol and evaluated for mRNA expression 
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levels of IL-7 and Flt3-ligand by qRT-PCR. IL-6 mRNA levels were also measured as a 
negative control since we did not anticipate IL-6 levels would be different. No significant 
difference was observed in mRNA levels of IL-7, IL-6 or Flt3-ligand in young mice (3 months 
old, N=3/genotype) as well as IL-6 or IL-7 levels in old mice (18 months old, 3-6/genotype) 
(FIGURE 3.4). However, these results queried total bone marrow levels and do not exclude 
the possibility of smaller, local niche differences. 
 
In summary, exogenous IL-7 could partially rescue the reduction of CFU-PreB colonies 
observed in Hspa9+/- compared to Hspa9+/+ littermates in vitro. This response does not 
appear to be due to a difference in IL-7Rα cell surface expression and evaluation of bone 
marrow IL-7 expression revealed no large changes in vivo. However, this does not exclude 
the possibility of smaller, local niche changes in IL-7 concentration.  
 
4.3. Analysis of B-cell progenitors in Hspa9 knockdown mice 
As described in Chapter 2, homozygous knockout of Hspa9 was lethal prior to fetal liver 
formation, preventing analysis of Hspa9-/- B-cell progenitors. In order to evaluate the effect of 
>50% reduction of Hspa9, we utilized a previously described shRNA knockdown model. We 
previously reported 2 shRNA’s that reduce Hspa9 levels 50-70% in vivo (levels are 30-50% 
of control expression). The more severe knockdown vector yielded few YFP+ cells available 
for analysis at 1 month. Therefore, we chose to use the less severe shRNA vector for further 
studies (shRNA #3). Previously, knockdown of Hspa9 by this shRNA in a bone marrow 
transduction/transplantation model significantly reduced mature erythroid cells, erythroid 
progenitors and mature B-cells3. However, B-cell progenitors and precursors were not 
evaluated in this initial investigation.  
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We utilized this model to acutely reduce Hspa9 levels more than 50% in order to study B-
cell progenitors and precursors. Bone marrow was transduced with a control vector (shLUC) 
or a vector containing Hspa9-targeting shRNA (shHspa9) and transplanted into lethally 
irradiated recipient mice. Cells transduced with virus (YFP+) were sorted and the mRNA 
level of Hspa9 was confirmed to be 37% of control cells (i.e., 63% knockdown)(FIGURE 
3.5). YFP+ bone marrow cells with knockdown of Hspa9 (shHspa9) had significantly 
reduced CFU-PreB colony formation compared to control (shLUC) cells (p=0.017, N=5-6 
mice/genotype) (FIGURE 3.6).  
 
In addition to colony forming ability, this model allowed us to interrogate stage-specific 
defects in B-cell maturation. Our results show a significant reduction in all Hardy fractions in 
YFP+ shHspa9 bone marrow (1.5-5.75 fold reduction), with the most notable difference in 
Hardy fraction D compared to control bone marrow (N=9 mice/group, p<0.05). YFP+ Hardy 
fractions B-F in the spleen of shHspa9 mice were also significantly reduced (1.7-3.5 fold, 
N=8 mice/group, p<0.05); however, fraction A was not significantly different when compared 
to control spleen cells (FIGURE 3.7). Fraction A cells are extremely rare in the spleen which 
may account for why we observe no difference. As previously described, the frequency of 
mature myeloid (Gr1+) and T-cell (CD3e+) populations were not significantly different 
following knockdown of Hspa9 (data not shown).  
 
Acute reduction of Hspa9 levels (37% of control levels) in a bone marrow 
transduction/transplantion model resulted in a significant reduction in all Hardy Fractions of 
the bone marrow and a significant reduction in CFU-PreB colony formation, supporting a 
role for Hspa9 in B-cell progenitor development. 
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4.4. Signaling downstream of the IL-7 receptor is altered in B-cells following Hspa9 
knockdown 
Exogenous addition of the early B-cell promoting cytokine IL-7, but not Flt3-Ligand, is able 
to partially overcome the reduction in CFU-PreB colonies observed in Hspa9+/- mice, 
indicating loss of Hspa9 may alter downstream IL-7R signaling. In order to further 
investigate the role of Hspa9 in IL-7 receptor signaling, we utilized the IL-7 dependent cell 
line known as B7 cells and Hspa9-targeting siRNAs18. The B7 cell line was made IL-7 
dependent through stable integration of MSCV-mIL7R-IRES-GFP in the IL-3-dependent 
Ba/F3 cell line. We used a combination of flow cytometry and Western blot analysis to query 
downstream effectors of the IL-7R pathway.  
 
4.4.1. Loss of Hspa9 reduces B7 cell growth 
We first tested the effects of IL-7 withdrawal on B7 cells. B7 cells are usually maintained 
in media containing 10ng/mL mIL-7. At lower concentrations of IL-7, B7 cells stop 
proliferating, allowing us to define the minimum dose of IL-7 required for normal B7 
growth (FIGURE 3.8). B7 cells were electroporated with Hspa9-targeting siRNAs. 
Knockdown of Hspa9 in B7 cells grown in sufficient amounts of IL-7 causes a reduction 
in cell numbers over time compared to B7 cells electroporated with non-targeting siRNA 
control. This result is similar to the reduction observed when cells are grown in low 
concentrations of IL-7 (FIGURE 3.8). 
 
4.4.2. Rapid Stat5 phosphorylation can be measured by flow cytometry of B7 
cells 
IL-7 stimulation rapidly induces tyrosine phosphorylation of the IL-7 receptor and several 
downstream targets24. We used B7 cells to query downstream targets of IL-7 by starving 
them of IL-7, which reduced phosphorylation of downstream targets, and spiking the 
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media with IL-7 to induce signaling through the IL-7 receptor. Stat5 is indispensible for 
B-cell development and is rapidly activated by phosphorylation by IL-7 stimulation of the 
IL-7 receptor25. We used flow cytometry to evaluate phospho-Stat5 levels to optimize 
starvation and stimulation periods. Overnight starvation resulted in the largest shift in 
pStat5 levels by flow cytometry and almost undetectable levels by Western blot. Spiking 
cultures with 10ng/mL IL-7 rapidly induced phosphorylation of Stat5 with maximal 
detection 30 minutes following stimulation and high pStat5 levels at later time points 
(FIGURE 3.9). 
 
4.4.3. Activation of Stat5, a major IL-7R downstream signaling molecule, is 
reduced by loss of Hspa9 
B7 cells were electroporated with Hspa9-targeting siRNAs and allowed to rest for three 
days to ensure recovery from electroporation. At this time, Hspa9 protein levels were 
reduced more than 50% (FIGURE 3.8). B7 cells were then starved of IL-7 overnight and 
stimulated with different concentrations of IL-7 (0.1, 1 or 10ng/mL). Cells were collected 
at 4 time points following stimulation (5, 10, 15 and 30 minutes) for flow cytometry or 2 
time points (10 and 30 minutes) for Western blot to evaluate phosphorylation of 
downstream targets. Phosphorylation of Stat5 was reduced at all time points and 
concentrations when evaluated by flow cytometry in B7 cells treated with siRNA against 
Hspa9 (FIGURE 3.9). These results were confirmed by Western blot of cells following 
stimulation with 1ng/mL IL-7 (FIGURE 3.9). 
 
Collectively, these results suggest that Stat5 phosphorylation is reduced following IL-7R 
stimulation in cells with reduced levels of Hspa9, in vitro. We next tested whether this 
occurred in vivo. 
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4.5. Loss of Hspa9 prolongs survival of mice in a BCR-ABL induced leukemia model 
Isolation and measurement of rare B-cell progenitor populations in vivo limited our ability to 
test Stat5 activation in Hspa9+/- mice. Therefore, we used a model system that is dependent 
on B-cell Stat5 activation. IL-7R signaling is a key mediator of B-cell differentiation and 
proliferation. During basal rates of lymphopoiesis in vivo, B-cells may be able to compensate 
for delayed or reduced IL-7R signaling through cross talk with other cytokines or increased 
levels of IL-7 in the local niche. However, when B-cell progenitors are pressed to rapidly 
proliferate by the introduction of an oncogene (BCR-ABL), this defect may reduce the rate of 
proliferation and therefore delay the onset of oncogene-induced leukemia. 
 
To investigate whether Hspa9+/- B-cell progenitors were able to rapidly proliferate in 
response to stress in vivo, we utilized an MSCV-p210-BCR/ABL-IRES-GFP system. When 
F1 mice generated from an FVB x C57Bl/6 cross are transplanted with bone marrow 
transduced with MSCV-p210-BCR/ABL-GFP, they rapidly develop and succumb to B-ALL26. 
This leukemia development requires rapid expansion of B-cell progenitors and BCR-ABL 
leukemias are known to be Stat5 dependent27-30. Survival is prolonged in mice that received 
Hspa9+/- compared to mice that received Hspa9+/+ bone marrow transduced with BCR/ABL, 
suggesting Stat5 activation may be reduced in vivo in Hspa9+/- mice (N=20/genotype, 
p=0.045, representative of 3 independent cohorts)(FIGURE 3.10). 
 
5. Discussion 
We have shown that Hspa9+/- mice have a hematopoietic cell-intrinsic reduction in CFU-PreB 
colony numbers that is not due to a difference in B-cell progenitor frequency. In order to 
investigate how loss of Hspa9 can affect B-cell progenitor function, we first investigated gene 
expression changes in CFU-PreB colonies from Hspa9+/- and Hspa9+/+ controls. Although we did 
not observe large unsupervised differences in gene expression between genotypes, supervised 
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analysis identified that genes with significantly reduced expression were enriched in pathways 
associated with proliferation and B-cell activation. With this analysis, we may have missed 
larger changes in gene expression that occurred in the cultures at earlier time points due to cell 
death induced by loss of Hspa9. This discovery did, however, lead us to further pursue signaling 
pathways key to B-cell progenitor proliferation (e.g., IL-7 receptor signaling).  
 
IL-7 is the only cytokine added to CFU-PreB methylcellulose culture media. Therefore, we first 
focused on IL-7R signaling. Although relative levels of IL-7 expression in whole bone marrow 
was not altered in Hspa9+/- mice compared to Hspa9+/+ littermates, in vitro responses to IL-7 
differed. The addition of higher concentrations of exogenous IL-7 to CFU-PreB cultures was 
able to partially rescue the number of CFU-PreB colonies from Hspa9+/- mice, but had no effect 
on colonies from wild-type littermates, indicative of blunted IL-7R signaling in Hspa9+/- B-cells. 
Several possible explanations exist for the lack of increased IL-7 expression in bulk bone 
marrow from Hspa9+/- versus Hspa9+/+ mice. First, local (i.e., niche specific) concentrations of IL-
7 may be different in Hspa9+/- mice, which could account for the observed in vivo compensation. 
However, if this were the case, B-cell progenitors would likely be outcompeted in a competitive 
transplant setting, which was not observed at steady state or following B-cell stress. Second, 
local IL-7 concentrations may be high enough in vivo that Hspa9+/- B-cell progenitors are not 
significantly affected. Third, CFU-PreB media contains only IL-7, while in vivo B-cell 
differentiation and proliferation are regulated by multiple cytokines that may contribute to in vivo 
compensation23,31-33. Flt3-ligand acts synergistically with IL-7 to promote expansion of 
hematopoietic progenitors32. However, the addition of Flt3-ligand to CFU-PreB media was 
unable to restore CFU-PreB colony formation by Hspa9+/-. Although this was not mediated by 
Flt3-ligand, cross talk between multiple signaling pathways may allow Hspa9+/- cells to be less 
IL-7 dependent in vivo. For example, Stat proteins can compensate for the loss of each other. 
Like many cytokine signaling pathways, IL-7R utilizes the Jak/Stat pathway, primarily activating 
	   123	  
Stat3 and Stat5a/b24,25. In one example, loss of Stat5 in hepatocytes led to inappropriate 
activation of Stat1 and Stat3 through reduced expression of negative regulators of Stat 
signaling, resulting in compensation for the loss of Stat5 signaling in these cells34. 
 
In order to test whether loss of Hspa9 altered IL-7R signaling, we analyzed downstream targets 
in an IL-7 dependent murine B-cell line. We first focused on Stat5 for the following reasons. 
Stat5 is a critical target of IL-7R signaling and is responsible for inducing expression of pro-
survival and pro-proliferation genes24,35,36. B-lymphopoiesis in Stat5a-/-/b-/- mice is arrested at the 
pre-pro B stage25,34,37. Overexpression of Stat5 can restore B-cell development in IL-7-/- mice, 
indicating it is the primary target of IL-7R signaling38,39. Indeed, we show by flow cytometry and 
Western blot that Stat5 phosphorylation following IL-7R stimulation is impaired by knockdown of 
Hspa9. Total levels of Stat5 do not appear to change by Western blot following knockdown of 
Hspa9, indicating that activation, not expression, of Stat5 may be regulated by Hspa9. 
 
One possible mechanism for how Hspa9 could regulate Stat5 is through its J-protein Dnaja3, 
which has been shown to be a negative regulator of Stat5b40. Dnaja3 is the J protein associated 
with Hspa9’s non-mitochondrial import functions and recruits substrates to Hspa941. 
Phosphorylation of Stat5 by cytokine stimulation resulted in disassociation of Dnaja3 from 
Stat5b in two IL-7 responsive B-cell lines (697 pre-B cells and Ba/F3, the B7 parental pro-B cell 
line)40. Conversely, increasing amounts of Dnaja3 resulted in dose-dependent inhibition of Stat5 
phosphorylation, cell growth, and expression of the Stat5 target Bcl-xl. Therefore, reduced 
levels of the highly expressed Hspa9 may increase the cellular availability of its J protein, 
Dnaja3. Increased Dnaja3 availability, in turn, may bind Stat5b, inhibiting its phosphorylation 
and reducing the expression of Stat5 target genes.  
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In a similar fashion, Hspa9 and Dnaja3 proteins have been implicated in opposing regulation of 
another transcription factor, p5342-44. Dnaja3 overexpression promotes p53 mitochondrial 
translocation and apoptosis while a reduction in Hspa9, which binds p53 in the cytoplasm, 
results in translocation of p53 into the nucleus. Hspa9 and Dnaja3 may regulate Stat5 
translocation in a similar way through protein interactions. In addition to nuclear translocation, 
Stat5, but not Stat3 or Stat1, was shown to translocate to the mitochondria following cytokine 
stimulation in Ba/F3 cells and to stimulate mitochondrial DNA transcription45. Like its pro-
apoptotic role in p53 regulation, Dnaja3 may promote apoptosis by preventing the translocation 
of Stat5 and thus prevent up-regulation of pro-survival signals. Meanwhile, Hspa9 may act 
antagonistically to this process by binding Dnaja3. Future studies of Stat5 regulation by Dnaja3 
and Hspa9 could be informed by prior studies of p53 regulation by Dnaja3 and Hspa9. 
 
Dnaja3 was also shown to reduce levels of Stat5b, but not Stat5a, following overexpression of 
Dnaja3; however, the mechanism of this inhibition is unknown. Although we do not see changes 
in total Stat5 levels following Hspa9 knockdown, we utilized an antibody that recognizes both 
Stat5a and Stat5b. Therefore, our use of a pan Stat5 antibody may have masked an effect on 
Stat5b levels. Future studies utilizing Stat5a and Stat5b specific antibodies will be required to 
determine if Stat5b levels are altered by Hspa9 knockdown. 
 
While our B-cell progenitor signaling studies have focused on IL-7R signaling, signaling of the 
pre-B cell receptor (pre-BCR) is another important receptor for B-lymphopoiesis. As B-cells 
differentiate and migrate away from the HSC niche, IL-7 becomes less available and B-cells 
become more IL-7 sensitive46,47. During this transition, B-cells undergo selection for appropriate 
pre-BCR rearrangement and expression. Effective rearrangement and expression of the pre-
BCR makes pro-B cells more sensitive to lower doses of IL-7 through cross talk of pathways 
downstream of both the IL-7R and the pre-BCR such as the PI3K and MAPK/Erk pathways48-52. 
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Both Erk1/2 and PI3K signaling promote B-cell proliferation and differentiation51,52. Conditional 
knockout of Erk1/2 in mice (Erk1-/-/2-/-) have a block in B-cell differentiation at the pro-B to pre-B 
transition, and conditional knockout of two PI3K isoforms in mice (p110α-/-δ-/-) resulted in a block 
at the pre-B stage49,53. Using our system, we identified no differences in total levels of Erk1/2 or 
Akt, a key downstream target of PI3K (data not shown). Our investigation of Erk1/2 activation is 
ongoing and will be discussed further in Chapter 4, and although we could readily detect Akt in 
B7 cells, we were unable to detect phosphorylation of Akt in B7 cells stimulated with IL-7. These 
results are consistent with another report using IL-7R expressing Ba/F3 cells derived 
independently of the B7 cells we have used, suggesting pAkt is not a dominant downstream 
target of IL-7R signaling in B7 cells32. However, whether Hspa9 is involved in the activation of 
Akt by the Pi3K pathway in pre-B cells should be addressed in future studies and will be 
discussed further in Chapter 4. 
 
Although our novel Hspa9+/- mouse models the heterozygous loss of human HSPA9 in MDS, 
possible differences exist and may indicate that >50% knockdown of Hspa9 is required for 
hematopoietic dysfunction in mice. Previous studies have demonstrated that HSPA9 mRNA is 
50% reduced in patients with MDS10. However, HSPA9 has not been measured at the protein 
level, which could be lower. Post-translational modifications of unknown function have been 
identified for HSPA954,55. Such modifications may affect its stability or localization. Additionally, 
the threshold for dysfunction due to loss of Hspa9 may be different in mice, requiring >50% 
knockdown to recapitulate dysfunction observed in humans. Homozygous loss of Hspa9 is 
lethal prior to fetal liver formation, so they could not be used for further hematopoietic studies. 
To investigate the effects of >50% loss of Hspa9, we transduced bone marrow cells with virus 
carrying an shRNA that targets Hspa9 and transplanted these cells into lethally irradiated 
recipients. Achieving 63% knockdown of Hspa9 mRNA, we first set out to determine the colony 
forming ability of bone marrow following Hspa9 knockdown and observed a reduction in CFU-
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PreB colony formation similar to what is seen in Hspa9+/- mice. In vivo, >50% knockdown of 
Hspa9 resulted in a significant reduction in B-cell progenitors and precursors (CLPs and Hardy 
fractions) when compared to control mice. Collectively, these studies strongly imply appropriate 
HSPA9 expression levels may be needed in normal human B-cell lymphopoiesis. 
 
These results led us to further investigate the effects of Hspa9 loss on B-cells in vivo. We 
utilized a Stat5-dependent system to induce B-ALL in Hspa9+/- and Hspa9+/+ littermates. Stat5 is 
constitutively activated and required for transformation and leukemic development by Abelson 
oncogenes, including the BCR-ABL fusion24,27-30,56. The rapid onset of BCR-ABL-induced 
leukemia requires rapid proliferation of the very small percentage of cells transduced with BCR-
ABL in order to become the dominant clone. We hypothesized that cells with impaired Stat5 
signaling would be unable to rapidly proliferate, resulting in longer leukemic latency. Although 
mild, the prolonged survival of mice that received Hspa9+/- bone marrow versus Hspa9+/+ bone 
marrow following BCR-ABL transduction was consistent across three cohorts of transplanted 
mice. Further investigation of the distribution of leukemic subtypes is ongoing and may reveal 
additional differences in B-cell phenotypes (i.e., Hardy fractions) between leukemias induced in 
Hspa9+/- and Hspa9+/+ mice. 
 
Collectively, we have demonstrated Hspa9 is involved IL-7R signaling. Gene expression 
pathways associated with B-cell signaling and activation are significantly reduced in CFU-PreB 
colonies from Hspa9+/- mice. Further analysis of IL-7R signaling revealed impaired Stat5 
activation following IL-7 stimulation of B7 cells treated with siRNA against Hspa9. Future 
experiments will reveal whether Stat5 activation is altered in B-cells of MDS patients with 
del(5q), contributing to the observed reduction in B-cell progenitors.  
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Figure 3.1: Hspa9+/- B-cells isolated from CFU-PreB culture have an ~50% reduction in 
Hspa9 mRNA expression 
Bone marrow from Hspa9+/- or Hspa9+/+ mice was plated in CFU-PreB culture media. On day 7, 
colonies were counted and cells were isolated from methylcellulose. RNA from B220+ cells was 
hybridized to Mouse Gene 1.0 ST arrays (Affymetrix) and analyzed for mRNA expression. 
Levels of Hspa9 mRNA were ~50% reduced in Hspa9+/- samples compared to Hspa9+/- samples 
(N=5/genotype). Statistical analysis by two tailed Student’s t-test. Error bars represent mean ± 
SD. 
 
Figure 3.2: The cell cycle distributions of Hspa9+/- bone marrow and spleen B-cell 
fractions are not different than Hspa9+/+ B-cell fractions 
Bone marrow (black circles) and spleen cells (blue circles) from 2 month old Hspa9+/- and 
Hspa9+/+ littermates were isolated and stained for cell surface markers prior to fixation and 
permeabilization for intracellular staining. Cells were stained for Ki67 and DAPI for cell cycle 
analysis (top panel, cells in G0/G1 of cell cycle; bottom panel, cells in G2/M/S of cell cycle). 
Hardy fractions are divided as follows: A-D (B220+, IgM-, IgD-), E (B220+, IgM-, IgD+) and F 
(B220+, IgM+, IgD+). (BM, bone marrow; Spl, Spleen) 
 
Figure 3.3: Exogenous IL-7, but not Flt3-ligand, partially rescues the reduction in Hspa9+/- 
CFU-PreB colony formation 
Bone marrow from Hspa9+/- (red bars) or Hspa9+/+ mice (white bars) was harvested and grown 
in methylcellulose containing 10ng/mL IL-7 (M3630 media) supplemented with additional A) IL-7 
(N=6/genotype) or B) Flt-3 ligand (N=3/genotype). Hspa9+/- colony numbers were significantly 
increased following the addition of exogenous IL-7 (one-way ANOVA, p=0.01) while Hspa9+/+ 
colony numbers were significantly decreased with increasing IL-7 (one-way ANOVA, p<0.01). 
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No change was seen in either genotype after addition of Flt3-Ligand. Error bars represent mean 
± SD. 
 
Figure 3.4: Total bone marrow expression of IL-7, IL-6 and Flt3-ligand are not different in 
Hspa9+/- mice 
Femurs from Hspa9+/- (grey bars) and Hspa9+/+ littermates (white bars) at 3 months (solid bars) 
and 18 months of age (checkered bars) were flushed with Trizol. Expression of A) IL-7, B) Flt3-
ligand and C) IL-6 were measured by qRT-PCR (N=3-6/genotype). Error bars represent mean ± 
SD. 
 
Figure 3.5: Hspa9 expression levels are reduced more than 50% by shRNA-mediated 
knockdown 
A) Expression of Hspa9 analyzed by qRT-PCR in bone marrow cells from Hspa9+/+ (open 
circles) and Hspa9+/- mice (filled circles) (N=3mice/genotype) compared to YFP+ bone marrow 
cells sorted from mice that received Fcysi-shLUC (open squares) and Fcysi-shHspa9 (filled 
squares) transduced bone marrow (N=7-8mice/group). Reduction of Hspa9 at the mRNA level 
is greater in shRNA-mediated knockdown (63%) than observed in heterozygous knockout mice 
(Hspa9+/-, 47%). B) Expression of Gm26109 in the same bone marrow populations showing 
shRNA-mediated knockdown does not alter Gm26109 expression. Error bars represent mean ± 
SD. 
 
Figure 3.6: CFU-PreB colony numbers are significantly reduced in mice that received 
Fcysi-shHspa9-transduced bone marrow 
YFP+ sorted bone marrow cells from Fcysi-shLUC or Fcysi-shHspa9 mice 10-12 weeks post-
transplant were plated in CFU-PreB methylcellulose medium. CFU-PreB colonies were counted 
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on day 7 and significantly reduced in Fcysi-shHspa9 mice (p=0.017). Statistical analysis by two 
tailed Student’s t-test. Error bars represent mean ± SD. 
 
Figure 3.7: Significant reduction in B-cell progenitors in mice following 
lentviral-mediated knockdown of Hspa9 
Frequency of bone marrow and spleen cells from mice 8-12 weeks following transplantation with 
bone marrow transduced with lentivirus containing control (shLUC) or Hspa9-targeting shRNA 
(shHspa9). A) The frequency of YFP+ cells is significantly reduced in the bone marrow and 
spleens of mice that received shHspa9-transduced bone marrow (red circles) compared to 
shLUC-transduced control (blue circles), as previously described3. The frequency of CLP’s (B) 
and Hardy fractions A-F from the bone marrow (C) and spleen (D) within the YFP+ population of 
recipient mice is significantly reduced. Statistical analysis by two tailed Student’s t-test. Error 
bars represent mean ± SD. *p<0.05, **p<0.01, ***p<0.001 
 
Figure 3.8: Reduction in IL-7 levels and knockdown of Hspa9 in IL-7 dependent cells (B7) 
reduces cell counts in culture 
B7 cells were electroporated with a non-targeting siRNA or siRNA targeting Hspa9. The 
following day (Day 1), cells were counted and replated at the same cell concentration. Cells 
were maintained at <1 million cells/mL and counted each day. A) Hspa9 levels were evaluated 
by Western blot on day 2. B) Growth of B7 cells maintained in 10ng/mL IL-7 is significantly 
inhibited by knockdown of Hspa9 by two independent Hspa9-targeting siRNAs (Day 4 siRNA 1 
vs Control, N=3/group, p=0.004, Students t-test).  C) Lowering the concentration of IL-7 in the 
media also reduces cell counts (N=2). Error bars represent mean ± SD. 
 
Figure 3.9: Stat5 activation by IL-7 receptor signaling is reduced in B7 cells following 
knockdown of Hspa9 
	   130	  
B7 cells were starved of cytokine overnight and spiked with various concentrations of IL-7 to 
stimulate phosphorylation of Stat5. Lysates were collected at designated times. A) 
Representative histogram of flow cytometry results showing activation of pStat5 in B7 cells 
starved overnight (grey line) and following IL-7 stimulation at different time points (colored 
histograms). B) Geometric mean of pStat5 fluorescence measured by flow cytometry over time 
showing maximal signaling 30 minutes after IL-7 stimulation. C) Left panel: Representative flow 
cytometry histogram showing reduced pStat5 levels in Hspa9 knockdown cells 5 minutes after 
B7 cells were stimulated with 1ng/mL IL-7 (Grey, IL-7 starved cells; Blue, Hspa9-targeting 
siRNA; Red, non-targeting siRNA). Right panel: The geometric mean of pStat5 fluorescence is 
depicted for cells treated with non-targeting control (solid lines) or Hspa9-targeting siRNA 
(dashed lines) following IL-7 stimulation with 0.1ng/mL (green lines) or 1ng/mL (red lines). 
Similar results were noted with 10ng/mL IL-7 stimulation (data not shown). Geometric mean of 
pStat5 in B7 cells starved of IL-7 is shown (dotted black line). Representative data is shown 
from 3 biological replicates. D) Western blot of lysates from B7 cells treated with Hspa9-
targeting siRNA or non-targeting control were analyzed for Stat5 phosphorylation. Cells were 
grown in 10mg/mL IL-7 for 4 days (Lane 1 and 2). Cells were starved overnight starting on day 3 
(Lane 3 and 4). Cells were starved overnight and stimulated on day 4 with 1ng/mL IL-7 and 
lysates were collected after 10 minutes (Lane 5 and 6) and 30 minutes (Lane 7 and 8). Levels of 
Stat5 phosphorylation, but not total Stat5, were reduced in cells treated with Hspa9-targeting 
siRNA. Representative data is shown from 4 biological replicates. 
 
Figure 3.10:  Prolonged survival of BCR-ABL induced leukemia in Hspa9+/- mice 
Induction of leukemia by BCR-ABL was previously shown to be Stat5-dependent. Survival of 
recipients that received MSCV-p210-IRES-GFP transduced Hspa9+/- bone marrow was 
extended compared to Hspa9+/+ recipients (p=0.045, Log-rank test). Data includes 3 
independently transduced and transplanted cohorts of mice (N=20 mice/genotype).  
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Table 3.1: Enriched pathways in genes significantly down-regulated in Hspa9+/- 
CFU-PreB colonies 
 
 
Annotation Cluster 1: Enrichment Score 5.02 
Term # genes PValue Benjamini 
GO:0045321 leukocyte activation 13 5.56E-06 6.28E-03 
GO:0046649 lymphocyte activation 12 8.65E-06 4.89E-03 
GO:0001775 cell activation 13 1.80E-05 6.77E-03 
Annotation Cluster 2: Enrichment Score 3.48 
GO:0051249 regulation of lymphocyte activation 9 1.94E-04 5.36E-02 
GO:0032944 regulation of mononuclear cell proliferation 7 2.51E-04 5.53E-02 
GO:0050670 regulation of lymphocyte proliferation 7 2.51E-04 5.53E-02 
GO:0070663 regulation of leukocyte proliferation 7 2.87E-04 5.28E-02 
GO:0002694 regulation of leukocyte activation 9 3.07E-04 4.85E-02 
GO:0050865 regulation of cell activation 9 3.35E-04 4.64E-02 
GO:0050863 regulation of T cell activation 7 1.24E-03 1.31E-01 
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CHAPTER 4: 
Ongoing Work and Future Directions 
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1. Ongoing work 
1.1. Does Hspa9 knockdown alter activation of Jak1 or Jak3 downstream of the IL-7R? 
In Chapter 3 we showed Stat5 activation/phosphorylation was reduced following knockdown 
of Hspa9 in B7 cells. Binding of IL-7 to the IL-7Rα chain induces recruitment of the common 
γ-chain. Heterodimerization brings together the Jak proteins associated with each chain, 
resulting in trans-phosphorylation of γ-chain-associated Jak3 and IL-7Rα-associated Jak11,2. 
For proper activation of Stat5, phosphorylation of Jak1 and Jak3 must occur2. We are using 
the same system described in Section 4.3 of Chapter 3 in B7 cells to evaluate Jak1 and 
Jak3 activation. Briefly, B7 cells are electroporated with siRNA against Hspa9 or non-
targeting control and 3 days later starved of IL-7 overnight followed by stimulation with 
1ng/mL IL-7. Whole cell lysates are collected at 10 and 30 minutes after stimulation. Our 
initial results show that Jak1 and Jak3 total levels are unchanged following IL-7 stimulation 
with or without Hspa9 knockdown, indicating that Hspa9 does not effect Jak1 or Jak3 
stability or expression. These experiments are being repeated and activation of Jak1 and 
Jak3 by phosphorylation is being evaluated.  
 
1.2. Does Hspa9 knockdown reduce Erk1/2 activation following IL-7R stimulation? 
As mentioned in Chapter 3, we have evaluated total Erk1/2 levels in B7 cells following IL-7 
stimulation and observed no difference between cells that received anti-Hspa9 siRNA or 
control siRNA. These experiments have been repeated more than 3 times utilizing biological 
replicates with the same result. Evaluation of Erk1/2 phosphorylation is ongoing; however, 
starving B7 cells of IL-7 overnight causes only a mild reduction in the levels of activated 
Erk1/2 present. In comparison, pStat5 levels are reduced to an almost undetectable level 
following overnight starvation. This mild reduction in pErk1/2 levels limits the dynamic range 
of the assay and indicates Erk1/2 phosphorylation also occurs in B7 cells independently of 
the IL-7R pathway. 
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1.3. Is the subtype of BCR-ABL induced leukemia different in Hspa9+/- mice compared 
to Hspa9+/+ mice? 
In Chapter 3, Section 4.5 we showed that mice that receive Hspa9+/- bone marrow have 
prolonged survival following BCR-ABL induced leukemia compared to mice that receive 
Hspa9+/+ bone marrow. BCR-ABL has been shown to induce different subtypes of B-ALL, 
specifically pro-B and pre-B. We will also determine the frequency of B-ALL in this cohort 
since BCR-ABL is able to induce a variety of hematopoietic malignancies, including chronic 
myeloid leukemia, myeloproliferative disorder, and T-ALL, depending on the strain of mice 
used, viral titer and the treatment of cells prior to transplant (i.e., 5-flurouracil treatment)3,4. 
Our method has been reported to produce almost all B-ALLs from C57Bl/6 x FVB F1 mice5. 
Cryopreserved bone marrow and spleen cells will be analyzed by flow cytometry using the 
Bethesda criteria and more stringent markers for pro-B and pre-B cells6. Control samples 
will be stained and analyzed alongside all leukemic samples. For subtyping of B-ALLs, we 
will use B220, CD43, CD24 and BP.1 to identify GFP+ leukemic populations as pro-B 
(GFP+, B220int, CD43+, CD24+, BP.1- ) or pre-B (GFP+, B220int, CD43+, CD24+, BP1+) 
subtypes. In addition to prolonged survival of BCR-ABL induced leukemia, we may observe 
differences in the subtypes of leukemia in mice that received Hspa9+/- bone marrow.  
 
1.4. Are there recurrent cooperating mutations induced by MOL4070LTR virus in 
Hspa9+/- mice? 
In Chapter 2, Section 4.9 we show that Hspa9+/- mice are not more susceptible than 
Hspa9+/+ mice to myeloid or lymphoid leukemia as a result of retroviral insertional 
mutagenesis. However, the common insertion sites identified from Hspa9+/- may be different 
than those identified in wild-type mice. We will identify common insertion sites in tumors 
banked from Hspa9+/- and Hspa9+/+ mice described in Chapter 2. HSPA9 is located in a 
	   148	  
commonly deleted region associated with transformation to acute myeloid leukemia. In mice, 
Hspa9 was identified as a common insertion site (CIS) in retroviral insertional mutagenesis 
screens in association with AML7,8. Hspa9 was also identified as a CIS in a large screen of 
genes that cooperate with the p19ARF-MDM2-p53 signaling pathway in acceleration of 
lymphomagenesis9. Common insertion sites unique to Hspa9+/- mice would identify genes 
that cooperate with Hspa9 loss to produce leukemia in mice and could be strong candidate 
genes for future studies. Future studies could include crossing Hspa9+/- mice with other 
appropriate mouse models (e.g., overexpression, knockout) for recurrently mutated genes 
and evaluate them for disease development. 
 
2. Future Directions 
2.1. Further analysis of Hspa9+/- mice 
2.1.1. Does the snoRNA Gm26109 contribute to alterations observed in B-cells? 
In Chapter 2, Section 4.5, we describe partial rescue of the CFU-PreB colony reduction 
by mild overexpression of HSPA9 in Hspa9+/- mice. We also describe a reduction in the 
expression of Gm26109, the snoRNA contained in intron 10 of Hspa9, in Hspa9+/- mice. 
In order to study the contribution of reduced expression of Gm26109 to this phenotype, 
overexpression of Gm26109 in mouse bone marrow can be used to assess whether it 
rescues the reduction in CFU-PreB colony number observed in Hspa9+/- mice. For this 
experiment, lineage depleted Hspa9+/- or Hspa9+/+ bone marrow are transduced with a 
lentivirus overexpressing Gm26109. The Fcy-si lentiviral vector (the same lentivirus used 
in Chapter 3, Section 4.3) has previously been used to overexpress snoRNAs in murine 
bone marrow10. The coding region of Gm26109 is cloned from murine genomic DNA into 
the Fcy-si vector. Overexpression will be evaluated by qRT-PCR as described in 
Chapter 2, Section 3.7.3. Transduced bone marrow is transplanted into lethally 
irradiated recipients. 8 weeks following transplant, mice are sacrificed and YFP+ cells 
	   149	  
are sorted for CFU-PreB methylcellulose assay, as described in Chapter 2, Section 4.5. 
The number of CFU-PreB colonies from both Hspa9+/- and Hspa9+/+ bone marrow 
transduced with either Fcy-siLUC-YFP control or Fcy-Gm26109-YFP virus are evaluated 
and compared. 
 
Alternatively, analysis of CFU-PreB colony formation in a conditional heterozygous 
knockout mouse that does not alter expression of Gm26109 could definitively answer 
this question. Creation of a conditional Hspa9 knockout mouse is an important future 
direction of this work and is an ongoing effort in the Walter lab. 
 
2.1.2. Is T-cell differentiation affected by loss of Hspa9 in vitro? 
IL-7R signaling is important for both B- and T-cell development. Therefore, T-cell 
potential from Hspa9+/- mice should be evaluated. Currently, no methylcellulose assay 
exists to analyze T-cell progenitors. However, T-cell differentiation can be evaluated by 
co-culture of hematopoietic progenitor cells with stromal cells that express the notch 
ligand delta-1 (OP9-DL1). For this experiment, 150 HSCs or 500 LMPPs from c-Kit-
enriched (autoMACS) cells are sorted directly into 24-well plates containing OP9-DL1 
stroma plated the previous day11. Opti-MEM media containing 10% FBS, 50µM β-
mercaptoethanol and 10µg/mL L-glutamine is supplemented with 10 ng/mL SCF, 10 
ng/mL FLT3L, and 10 ng/mL IL-7 to promote T-cell development, as previously 
described11. Cultures are evaluated on Day 20 for expression of T-cell 
immunophenotypic markers, as previously described. (CD44/CD25 to define DN1-DN4, 
CD4/CD8 for DP/SP stages)12,13. An inhibition, reduction or delay in T-cell development 
from Hspa9+/- stem and progenitor cells would indicate Hspa9 also plays a role in IL-7R 
signaling in T-cells.  
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2.1.3. Does loss of Hspa9 effect Stat5 activation in primary B-cell progenitors? 
In Chapter 3 we showed that knockdown of Hspa9 in an IL-7 dependent B-cell line led to 
reduced Stat5 activation. Future studies should include analysis of primary B-cell 
progenitors comparing Hspa9+/- and Hspa9+/+ mice. Using immunophenotypic markers 
defined in TABLE 2.5, CLPs and Hardy fractions A-D are sorted directly into IMDM 
media supplemented with 20% FBS lacking cytokines (pooling mice if necessary). 
Following a 1-hour rest period, 50,000-500,000 cells are resuspended in 0.5-1mL 
volume and stimulated with 10ng/mL IL-7. Cell lysates should be collected at 10 minutes 
(and 30 minutes if sample allows) following stimulation per our B7 protocol detailed in 
Chapter 3. Total and pStat5 levels are analyzed by Western blot. A reduction in pStat5 
levels is predicted to occur in Hspa9+/- mice compared to Hspa9+/+ littermates if in vivo 
compensation occurs via local IL-7 concentrations. 
 
Alternatively, pStat5 levels in a CLP-enriched population can be evaluated by flow 
cytometery as previously described14. Briefly, whole bone marrow cells from Hspa9+/- 
and Hspa9+/+ mice are collected, starved of IL-7 for 30 minutes and stimulated prior to 
collection. Cells are stained for cell surface markers, fixed with paraformaldehyde and 
permeabilized with methanol. Fixed and permeabilized cells are then stained with pStat5 
prior to flow cytometric analysis. Cells expressing lineage markers (B220, DX5, Gr1, 
CD11b, CD3e, CD8, Ter119) are excluded and pStat5 levels are measured in AA4.1+ 
cells. 
 
Finally, Stat5 activation could be investigated in primary MDS samples with and without 
del(5q). B-cell progenitors (CD34+CD10+CD19+/- cells) from MDS samples can be 
isolated by FACS and analyzed following IL-7 starvation and stimulation in culture.  
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2.2. How does Hspa9 regulate Stat5? 
2.2.1. Does Hspa9 interact directly with Stat5? 
Our results indicate Hspa9 inhibits activation of Stat5 following IL-7 stimulation of IL-7R. 
To investigate the mechanism through which this occurs, co-immunoprecipitation 
experiments should be performed in order to determine if Hspa9 directly interacts with 
Stat5. Both endogenous and overexpression of tagged Hspa9 have been successfully 
co-immunoprecipitated with other proteins15-17. Since Hspa9 is a chaperone protein, it is 
important to determine whether this interaction occurs within the substrate binding 
domain which lacks protein specificity or in a region that is more likely to have functional 
significance. This could be achieved by expressing tagged Hspa9 deletion mutants, as 
previously described16.  
 
2.2.2. Does Hspa9 inhibit Stat5 activation by increasing availability of its J 
protein, Dnaja3? 
In Chapter 3 we proposed a model explaining how Hspa9 could regulate activation of 
Stat5. In the proposed model, reduction of the ubiquitously expressed Hspa9 leads to 
increased cellular availability of its J protein Dnaja3. Previously, Dnaja3 overexpression 
was shown to inhibit phosphorylation of Stat5, inhibit activation of Stat5 downstream 
targets and reduce expression of Stat5b, but not Stat5a. To test this hypothesis, Stat5 
activation could be evaluated following knockdown of both Hspa9 and Dnaja3. 
Additionally, total levels of Stat5a and Stat5b should be evaluated separately to see if 
Stat5b total levels are reduced following knockdown of Hspa9 and restored by 
simultaneous knockdown of Dnaja3 in B7 cells.  
 
If loss of Hspa9 inhibits Stat5b function, we would predict that loss of Stat5a, which 
performs a largely redundant role with Stat5b during lymphopoiesis, would further impair 
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B-cell development in Hspa9+/- mice. CFU-PreB colony formation is normal in Stat5a-/- 
and Stat5b-/- mice but significantly reduced in Stat5a-/-b-/- mice18. These results indicate 
Stat5a and Stat5b can compensate for each other in B-lymphopoiesis. Stat5a may be 
responsible for in vivo compensation in Hspa9+/- mice if loss of Hspa9 inhibits Stat5b. In 
order to test whether Stat5a is responsible for in vivo compensation in Hspa9+/- mice, in 
vivo frequencies of Stat5a-/-Hspa9+/- versus Hspa9+/- B-cell progenitors could be 
evaluated by CFU-PreB methylcellulose assay and flow cytometry measurements of 
CLPs, Hardy fractions and mature B-cell populations. 
 
2.3. Does Hspa9 alter B-cell signaling pathways in human cells? 
The IL-7 dependent cell line utilized in Chapter 3 is a murine pro-B cell line. Additional 
studies utilizing the IL-7 responsive human pre-B cell line, 697 cells, may provide additional 
insights into other downstream signaling pathways such as the PI3K pathway19,20. Normal B-
cell development occurs in humans with severe combined immunodeficiency that have 
inactivating IL-7R mutations21. This data indicates that IL-7 is dispensable in humans. 
However, another key B-cell specific receptor, the pre-BCR, is required. Patients with 
mutations in components of the pre-BCR have a block in B-cell development at the pro-B 
stage3,4,22. Significant cross talk occurs between these receptors, resulting in signaling 
through Erk1/2 and PI3K by both6,23-25. Future studies should address these downstream 
signaling targets. Investigation of the impact of Hspa9 loss on signaling in 697 cells will 
allow analysis of both human cells and pre-BCR signaling. 
 
2.4. Does acute loss of Hspa9 result in hematopoietic defects? 
Hspa9+/- mice do not recapitulate the reduction in erythroid and B-cell progenitor frequencies 
observed with >50% knockdown of Hspa97,8,26. However, it is not clear whether this 
difference is due to the level of Hspa9 reduction or whether acute, shRNA-mediated 
	   153	  
knockdown escapes compensation. Hspa9+/- mice have a reduction in Hspa9 levels in every 
cell of the body throughout development, providing ample time for compensation to develop. 
Del(5q) is an acquired cytogenetic abnormality within a subset of hematopoietic cells in 
humans. It remains to be seen whether acute loss of Hspa9 in an adult mouse, as occurs in 
del(5q) MDS patients, will escape compensation and recapitulate the more severe 
hematopoietic defects observed in the knockdown model. A conditional knockout model 
would provide acute heterozygous or homozygous loss of Hspa9, as well as the ability to 
target loss to specific cellular subsets. For future investigations of lymphoid lineages, CD2-
Cre mice provide the expression of Cre at the earliest B- and T-cell stages and could be 
used to specifically study B- and T-cell development9,27. 
 
3. Conclusion 
Although Hspa9+/- mice show minimal hematopoietic abnormalities, ample evidence exists to 
support further investigation of its role in hematopoiesis and MDS. Here we present several 
outstanding questions to be addressed by future studies of Hspa9 in hematopoiesis. 
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